Tokushima University / Educator and Researcher Directory --- Saito-Tarashima, Noriko

Personal Web Page

https://researchmap.jp/noriko_s_t (researchmap)

Field of Study

○	Life sciences [Pharmaceuticals - chemistry and drug development]

Subject of Study

Book / Paper

Book:

1.	Noriko Saito-Tarashima and Noriaki Minakawa : Chemistry of Cyclic Dinucleotides and Analogs, Mar. 2023. (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85194015670 (Elsevier: Scopus)
2.	Noriko Saito-Tarashima and Noriaki Minakawa : 4'-チオ核酸によるセントラルドグマへの挑戦, Feb. 2023.
3.	Noriko Saito-Tarashima : COVID-19に対する治療薬をいち早くより多くの患者に届けるために, Sep. 2022.
4.	Noriko Saito-Tarashima and Noriaki Minakawa : 核酸科学ハンドブック, Dec. 2020.
5.	Noriko Saito-Tarashima and Noriaki Minakawa : 第16章化学修飾DNAを利用したRNAi創薬, Aug. 2018.
6.	Noriaki Minakawa, Akira Matsuda and Noriko Saito-Tarashima : RNA bioisoster: Chemistry and properties of 4'-thioRNA and 4'-selenoRNA, Springer, 2018.
7.	Noriko Saito-Tarashima, Akira Matsuda and Noriaki Minakawa : Four-hydrogen-bonding base pairs in oligonucleotides: design, synthesis and properties, Springer, 2018.
8.	Noriko Saito-Tarashima and Noriaki Minakawa : 第8章生物学的等価性を指向した化学修飾 DNA による核酸創薬研究, シーエムシ-出版, Apr. 2017.

Academic Paper (Judged Full Paper):

1.	Noriko Saito-Tarashima, Yuma Kagotani, Shuya INOUE, Mao Kinoshita and Noriaki Minakawa : Synthesis of 4-Thiomodified c-di-AMP Analogs, Current Protocols, Vol.3, No.9, e892, 2023. (Summary) Cyclic diadenosine monophosphate (c-di-AMP) is a bacterial cyclic dinucleotide (CDN) comprising two adenosine monophosphates covalently linked by two 3',5'-phosphodiester bonds. c-di-AMP works as a second messenger, regulating many biological processes in bacteria such as cell wall homeostasis, DNA integrity, and sporulation via specific protein and/or RNA receptors. Moreover, c-di-AMP can function as an immunomodulatory agent in eukaryote cells via the stimulator of interferon genes (STING) signaling pathway. This protocol describes the chemical synthesis of two c-di-AMP analogs with a sulfur atom at the 4'-position of the furanose ring instead of an oxygen atom: c-di-4'-thioAMP (1) and cAMP-4'-thioAMP (2). Analogs 1 and 2 have resistance to phosphodiesterase-mediated degradation and are therefore useful for understanding the diverse biological phenomena regulated by c-di-AMP. In this protocol, two 4'-thioadenosine monomers are initially prepared via a Pummerer-like reaction assisted by hypervalent iodine. The CDN skeleton is then constructed through two key reactions based on phosphoramidite chemistry: dimerization of two appropriately protected nucleoside monomers to produce a linear dinucleotide, followed by macrocyclization of the resulting linear dinucleotide to form the CDN skeleton. © 2023 Wiley Periodicals LLC. Basic Protocol 1: Preparation of 4'-thioadenosine monomers 13 and 14 Basic Protocol 2: Preparation of c-di-4'-thioAMP (1) and cAMP-4'-thioAMP (2). (Keyword) Dinucleoside Phosphates / Thionucleosides / Homeostasis / Cyclic AMP (Link to Publication Site) ● Publication site (DOI): 10.1002/cpz1.892 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37725690 ● Search Scopus @ Elsevier (PMID): 37725690 ● Search Scopus @ Elsevier (DOI): 10.1002/cpz1.892 (DOI: 10.1002/cpz1.892, PubMed: 37725690)
2.	Yuhei Nogi, Noriko Saito-Tarashima, Sangita Karanjit and Noriaki Minakawa : Synthesis and Behavior of DNA Oligomers Containing the Ambiguous Z-Nucleobase 5-Aminoimidazole-4-carboxamide, Molecules, Vol.28, No.7, 3265, 2023. (Summary) 5-Amino-1-β-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate (ZMP) is a central intermediate in de novo purine nucleotide biosynthesis. Its nucleobase moiety, 5-aminoimidazole-4-carboxamide (Z-base), is considered an ambiguous base that can pair with any canonical base owing to the rotatable nature of its 5-carboxamide group. This idea of ambiguous base pairing due to free rotation of the carboxamide has been applied to designing mutagenic antiviral nucleosides, such as ribavirin and T-705. However, the ambiguous base-pairing ability of Z-base has not been elucidated, because the synthesis of Z-base-containing oligomers is problematic. Herein, we propose a practical method for the synthesis of Z-base-containing DNA oligomers based on the ring-opening reaction of an -dinitrophenylhypoxanthine (Hxa) base. Thermal denaturation studies of the resulting oligomers revealed that the Z-base behaves physiologically as an A-like nucleobase, preferentially forming pairs with T. We tested the behavior of Z-base-containing DNA oligomers in enzyme-catalyzed reactions: in single nucleotide insertion, Klenow fragment DNA polymerase recognized Z-base as an A-like analog and incorporated dTTP as a complementary nucleotide to Z-base in the DNA template; in PCR amplification, Taq DNA polymerase similarly incorporated dTTP as a complementary nucleotide to Z-base. Our findings will contribute to the development of new mutagenic antiviral nucleoside analogs. (Keyword) Aminoimidazole Carboxamide / DNA / Base Pairing / Nucleosides / Nucleotides (Link to Publication Site) ● Publication site (DOI): 10.3390/molecules28073265 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37050028 ● Search Scopus @ Elsevier (PMID): 37050028 ● Search Scopus @ Elsevier (DOI): 10.3390/molecules28073265 (DOI: 10.3390/molecules28073265, PubMed: 37050028)
3.	Jinha Yu, Won Ji Kim, Girish Chandra, Noriko Saito-Tarashima, Yuhei Nogi, Masashi Ohta, Noriaki Minakawa and Shin Lak Jeong : Synthesis of oligonucleotides containing 5-homo-4-selenouridine derivative and its increased resistance against nuclease, Bioorganic & Medicinal Chemistry Letters, Vol.83, 129172, 2023. (Summary) As technologies using RNA or DNA have been developed, various chemical modifications of nucleosides have been attempted to increase the stability of oligonucleotides. Since it is known that 2'-OMe-modification greatly contributes to increasing the stability of oligonucleotides, we added 2'-OMe to our previously developed 4'-selenonucleoside and 5'-homo-4'-selenonucleoside as the modified monomers for oligonucleotide: 2'-methoxy-4'-selenouridine (2'-OMe-4'-Se-U) and 5'-homo-2'-methoxy-4'-selenouridine (5'-homo-2'-OMe-4'-Se-U). We synthesized oligonucleotides containing the chemically modified 4'-selenouridine and evaluated their thermal stability and nuclease resistance. In conclusion, the nuclease stability of the oligonucleotide containing 5'-homo-2'-OMe-4'-selenouridine increased while its thermal stability decreased. (Keyword) Oligonucleotides / Organoselenium Compounds / RNA / Uridine (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bmcl.2023.129172 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36746352 ● Search Scopus @ Elsevier (PMID): 36746352 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bmcl.2023.129172 (DOI: 10.1016/j.bmcl.2023.129172, PubMed: 36746352)
4.	Kou Motani, Noriko Saito-Tarashima, Kohei Nishino, Shunya Yamauchi, Noriaki Minakawa and Hidetaka Kosako : The Golgi-resident protein ACBD3 concentrates STING at ER-Golgi contact sites to drive export from the ER, Cell Reports, Vol.41, No.12, 111868, 2022. (Summary) STING, an endoplasmic reticulum (ER)-resident receptor for cyclic di-nucleotides (CDNs), is essential for innate immune responses. Upon CDN binding, STING moves from the ER to the Golgi, where it activates downstream type-I interferon (IFN) signaling. General cargo proteins exit from the ER via concentration at ER exit sites. However, the mechanism of STING concentration is poorly understood. Here, we visualize the ER exit sites of STING by blocking its transport at low temperature or by live-cell imaging with the cell-permeable ligand bis-SATE-2'F-c-di-dAMP, which we have developed. After ligand binding, STING forms punctate foci at non-canonical ER exit sites. Unbiased proteomic screens and super-resolution microscopy show that the Golgi-resident protein ACBD3/GCP60 recognizes and concentrates ligand-bound STING at specialized ER-Golgi contact sites. Depletion of ACBD3 impairs STING ER-to-Golgi trafficking and type-I IFN responses. Our results identify the ACBD3-mediated non-canonical cargo concentration system that drives the ER exit of STING. (Keyword) Ligands / Proteomics / Membrane Proteins / Endoplasmic Reticulum / Golgi Apparatus / Interferon Type I / Protein Transport (Tokushima University Institutional Repository) ● Metadata: 118576 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.celrep.2022.111868 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36543137 ● Search Scopus @ Elsevier (PMID): 36543137 ● Search Scopus @ Elsevier (DOI): 10.1016/j.celrep.2022.111868 (Tokushima University Institutional Repository: 118576, DOI: 10.1016/j.celrep.2022.111868, PubMed: 36543137)
5.	Masashi Ohta, Hiromi Takahashi, YUHEI Nogi, Yuma Kagotani, Noriko Saito-Tarashima, Jiro Kondo and Noriaki Minakawa : Synthesis and properties of fully-modified 4-selenoRNA, an endonuclease-resistant RNA analog, Bioorganic & Medicinal Chemistry, Vol.76, No.15, 117093, 2022. (Summary) A large number of chemically modified oligonucleotides (ONs) have been developed for RNA-based technologies. In most modified RNAs, the characteristic 2'-hydroxyl (2'-OH) groups are removed to enhance both nuclease resistance and hybridization ability. However, the importance of the 2'-OH group in RNA structure and function is well known. Here, we report the synthesis and properties of 4'-selenoRNA in which all four nucleoside units retain the 2'-OH groups but contain a selenium atom instead of an oxygen atom at the 4'-position of the furanose ring. 4'-SelenoRNA has enhanced ability to form duplexes with RNA, and high endonuclease resistance despite the presence of the 2'-OH groups. X-ray crystallography analysis showed that the 4'-selenoRNA duplex adopts an A-conformation, similar to natural RNA, although one 4'-selenocytidine residue has unusual South-type sugar puckering. Furthermore, preliminary studies using 4'-seleno-modified siRNAs suggest that 4'-selenoRNA may be applicable to RNA interference technology. Collectively, our results raise the possibility of a new class of modified RNA in which 2'-OH groups do not need to be masked. (Keyword) Endonucleases / RNA (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bmc.2022.117093 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36434923 ● Search Scopus @ Elsevier (PMID): 36434923 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bmc.2022.117093 (DOI: 10.1016/j.bmc.2022.117093, PubMed: 36434923)
6.	Noriko Saito-Tarashima, Mana Ueno, Akiho Murai, Ayako Matsuo and Noriaki Minakawa : Cas9-mediated DNA cleavage guided by enzymatically prepared 4-thio-modified RNA, Organic & Biomolecular Chemistry, Vol.20, No.26, 5245-5248, 2022. (Summary) CRISPR-Cas9-mediated DNA editing relies on guide RNAs (gRNAs) that direct site-specific DNA cleavage by the Cas endonuclease. Because natural gRNA is susceptible to intracellular degradation, it is desirable to chemically protect it for efficient editing. Using 4'-thioribonucleoside 5'-triphosphates and T7 transcription, we have prepared 4'-thio-modified gRNAs that guide Cas9-mediated DNA cleavage. This approach is a simple way to obtain chemically modified RNA suitable for CRISPR-Cas9 DNA editing. (Keyword) CRISPR-Cas Systems / DNA Cleavage / RNA / RNA, Guide, Kinetoplastida (Link to Publication Site) ● Publication site (DOI): 10.1039/d2ob00742h (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35726625 ● Search Scopus @ Elsevier (PMID): 35726625 ● Search Scopus @ Elsevier (DOI): 10.1039/d2ob00742h (DOI: 10.1039/d2ob00742h, PubMed: 35726625)
7.	Noriko Saito-Tarashima, Akiho Murai and Noriaki Minakawa : Rewriting the Central Dogma with Synthetic Genetic Polymers, Chemical & Pharmaceutical Bulletin, Vol.70, No.5, 310-315, 2022. (Summary) DNA and RNA are ubiquitous molecules responsible for storage and transmission of genetic information and together comprise the central dogma of molecular biology. However, the recent emergence of synthetic genetic polymers is providing an opportunity to challenge the fundamental principles of life. Herein, we describe the ongoing attempts to rewrite the central dogma with 4'-thioDNA and 4'-thioRNA, which feature a sulfur instead of an oxygen atom in the furanose ring moiety. Using reconstituted Escherichia coli gene expression machinery, studies have shown that the genetic information conserved in 4'-thioDNA can be transcribed to 4'-thioRNA and eventually translated into protein, mirroring the processes that occur in nature. Such studies underscore the feasibility of controlling life by substances other than DNA and RNA. (Keyword) DNA / Polymers / RNA (Link to Publication Site) ● Publication site (DOI): 10.1248/cpb.c21-00960 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35491185 ● Search Scopus @ Elsevier (PMID): 35491185 ● Search Scopus @ Elsevier (DOI): 10.1248/cpb.c21-00960 (DOI: 10.1248/cpb.c21-00960, PubMed: 35491185)
8.	Motoki Nakamura, Kentaro Uemura, Noriko Saito-Tarashima, Akihiko Sato, Yasuko Orba, Hirofumi Sawa, Akira Matsuda, Katsumi Maenaka and Noriaki Minakawa : Synthesis and Anti-dengue Virus Activity of 5-Ethynylimidazole-4-carboxamide (EICA) Nucleotide Prodrugs, Chemical & Pharmaceutical Bulletin, Vol.70, No.3, 220-225, 2022. (Summary) We previously showed that 5-ethynyl-(1-β-D-ribofuranosyl)imidazole-4-carboxamide (1; EICAR) is a potent anti-dengue virus (DENV) compound but is cytotoxic to some cell lines, while its 4-thio derivative, 5-ethynyl-(4-thio-1-β-D-ribofuranosyl)imidazole-4-carboxamide (2; 4'-thioEICAR), has less cytotoxicity but also less anti-DENV activity. Based on the hypothesis that the lower anti-DENV activity of 2 is due to reduced susceptibility to phosphorylation by cellular kinase(s), we investigated whether a monophosphate prodrug of 2 can improve its activity. Here, we first prepared two types of prodrug of 1, which revealed that the S-acyl-2-thioethyl (SATE) prodrug had stronger anti-DENV activity than the aryloxyphosphoramidate (so-called ProTide) prodrug. Based on these findings, we next prepared the SATE prodrug of 4'-thioEICAR 18. As expected, the resulting 18 showed potent anti-DENV activity, which was comparable to that of 1; however, its cytotoxicity was also increased relative to 2. Our findings suggest that prodrugs of 4'-thioribonucleoside derivatives such as EICAR (1) represent an effective approach to developing potent biologically active compounds; however, the balance between antiviral activity and cytotoxicity remains to be addressed. (Keyword) Antiviral Agents / Cell Line / Dengue Virus / Imidazoles / Nucleotides / Prodrugs / Virus Replication (Link to Publication Site) ● Publication site (DOI): 10.1248/cpb.c21-01038 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34955490 ● Search Scopus @ Elsevier (PMID): 34955490 ● Search Scopus @ Elsevier (DOI): 10.1248/cpb.c21-01038 (DOI: 10.1248/cpb.c21-01038, PubMed: 34955490)
9.	Naoto Hinotani, Noriko Saito-Tarashima and Noriaki Minakawa : Convenient Synthesis of 3-Deazapurine Nucleosides (3-Deazainosine, 3-Deazaadenosine and 3-Deazaguanosine) Using Inosine as a Starting Material, Current Protocols, Vol.1, No.11, e297, 2021. (Summary) A convenient synthetic method for preparing 3-deazapurine nucleosides (3-deazainosine, 3-deazaadenosine, and 3-deazaguanosine) from inosine via a 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) derivative, which is a key intermediate, is described. A large-scale synthesis of an EICAR derivative starting from inosine was achieved in six steps via dinitrophenylation at the N position followed by ring opening, iodination of the resulting 5-amino group, and a palladium-catalyzed cross-coupling reaction. The resulting EICAR derivative was then converted into 3-deazainosine, 3-deazaadenosine, and 3-deazaguanosine. This route enabled us to synthesize 3-deazapurine nucleosides conveniently in good yields. © 2021 Wiley Periodicals LLC. Basic Protocol 1: Preparation of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) derivative 6 Basic Protocol 2: Preparation of 3-deazapurine nucleosides 8, 11, and 14. (Keyword) Guanosine / Inosine / Nucleosides / Tubercidin (Link to Publication Site) ● Publication site (DOI): 10.1002/cpz1.297 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34837670 ● Summary page in Scopus @ Elsevier: 2-s2.0-85120332138 (DOI: 10.1002/cpz1.297, PubMed: 34837670, Elsevier: Scopus)
10.	Kentaro Uemura, Haruaki Nobori, Akihiko Sato, Takao Sanaki, Shinsuke Toba, Michihito Sasaki, Akiho Murai, Noriko Saito-Tarashima, Noriaki Minakawa, Yasuko Orba, Hiroaki Kariwa, William W. Hall, Hirofumi Sawa, Akira Matsuda and Katsumi Maenaka : 5-Hydroxymethyltubercidin Exhibits Potent Antiviral Activity against Flaviviruses and Coronaviruses, including SARS-CoV-2, iScience, Vol.24, No.10, 103120, 2021. (Summary) Newly emerging or re-emerging viral infections continue to cause significant morbidity and mortality every year worldwide, resulting in serious effects on both health and the global economy. Despite significant drug discovery research against dengue viruses (DENVs) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), no fully effective and specific drugs directed against these viruses have been discovered. Here, we examined the anti-DENV activity of tubercidin derivatives from a compound library from Hokkaido University and demonstrated that 5-hydroxymethyltubercidin (HMTU, HUP1108) possessed both potent anti-flavivirus and anti-coronavirus activities at submicromolar levels without significant cytotoxicity. Furthermore, HMTU inhibited viral RNA replication and specifically inhibited replication at the late stages of the SARS-CoV-2 infection process. Finally, we demonstrated that HMTU 5'-triphosphate inhibited RNA extension catalyzed by the viral RNA-dependent RNA polymerase. Our findings suggest that HMTU has the potential of serving as a lead compound for the development of a broad spectrum of antiviral agents, including SARS-CoV-2. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.isci.2021.103120 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34541466 ● Search Scopus @ Elsevier (PMID): 34541466 ● Search Scopus @ Elsevier (DOI): 10.1016/j.isci.2021.103120 (DOI: 10.1016/j.isci.2021.103120, PubMed: 34541466)
11.	Noriko Saito-Tarashima, Yusuke Kumanomido, Katsuyuki Nakashima, Yoshiyuki Tanaka and Noriaki Minakawa : Synthesis of a cyclic dinucleotide analog with ambiguous bases, 5-aminoimidazole-4-carboxamide, The Journal of Organic Chemistry, Vol.86, No.21, 15004-15010, 2021. (Summary) Cyclic dinucleotides (CDNs) are second messengers composed of two purine nucleotides. In recent years, the structural diversity of CDNs and their functionality in biological processes are being intensely studied. Herein we report the chemical synthesis of cyclic di-5-aminoimidazole-4-carboxamide-1-β-d-ribofuranosyl monophosphate (c-di-ZMP) (), which consists of two 5-amino-4-imidazolecarboxamide ribonucleotides (Z-ribonucleotides) linked via two phosphodiester linkages. Construction of the CDN skeleton with an -dinitrophenylhypoxanthine base (Hxa-base) by phosphoramidite chemistry and the subsequent ring-opening reaction of Hxa-base successfully yielded the desired . (Keyword) Imidazoles / Ribonucleotides (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.joc.1c01706 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34652132 ● Search Scopus @ Elsevier (PMID): 34652132 ● Search Scopus @ Elsevier (DOI): 10.1021/acs.joc.1c01706 (DOI: 10.1021/acs.joc.1c01706, PubMed: 34652132)
12.	Noriko Saito-Tarashima, Mao Kinoshita, Yosuke Igata, Yuta Kashiwabara and Noriaki Minakawa : Replacement of oxygen with sulfur on the furanose ring of cyclic dinucleotides enhances the immunostimulatory effect via STING activation, RSC Medicinal Chemistry, Vol.12, No.9, 1519-1524, 2021. (Summary) Cyclic dinucleotides (CDNs) are secondary messengers composed of two purine nucleotides linked two phosphodiester linkages: c-di-GMP, c-di-AMP, 3',3'-cGAMP, and 2',3'-cGAMP. CDNs activate the stimulator of interferon genes (STING) and trigger immune responses in mammalian species. CDNs are thus fascinating molecules as drug candidates, and chemically stable CDN analogues that act as STING agonists are highly desired at present. We herein report the practical synthesis of 4'-thiomodified c-di-AMP analogues, which have sulfur atoms at the 4'-position on the furanose ring instead of oxygen atoms, using simple phosphoramidite chemistry. The resulting 4'-thiomodified c-di-AMP analogues acted as potent STING agonists with long-term activity. Our results show that replacing O4' on CDNs with sulfur can lead to enhanced immunostimulatory effects STING activation. (Link to Publication Site) ● Publication site (DOI): 10.1039/d1md00114k (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34671735 ● Search Scopus @ Elsevier (PMID): 34671735 ● Search Scopus @ Elsevier (DOI): 10.1039/d1md00114k (DOI: 10.1039/d1md00114k, PubMed: 34671735)
13.	Rion Maeda, Noriko Saito-Tarashima, Hideaki Wakamatsu, Yoshihiro Natori, Noriaki Minakawa and Yuichi Yoshimura : Synthesis and Properties of 4-ThioLNA/BNA, Organic Letters, Vol.23, No.10, 4062-4066, 2021. (Summary) To develop a new nucleoside analogue applicable to oligonucleotide therapeutics, we designed a 4'-thio analogue of an LNA/BNA monomer. Synthesis of 4'-hydroxymethyl-4'-thioribonucleoside was achieved by a tandem ring-contraction-aldol reaction of a 5-thiopyranose derivative and the subsequent Pummerer-type thioglycosylation reaction of the corresponding sulfoxide. Treatment of 4'-hydroxymethyl-4'-thiopyrimidine nucleosides with diphenyl carbonate in the presence of catalytic NaHCO gave the desired 4'-thioLNA/BNA monomers, which were introduced into oligonucleotides. (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.orglett.1c01306 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33938754 ● Search Scopus @ Elsevier (PMID): 33938754 ● Search Scopus @ Elsevier (DOI): 10.1021/acs.orglett.1c01306 (DOI: 10.1021/acs.orglett.1c01306, PubMed: 33938754)
14.	Noriko Saito-Tarashima, Ayako Matsuo and Noriaki Minakawa : Gene Expression of 4'-Thioguanine DNA via 4'-Thiocytosine RNA., Journal of the American Chemical Society, Vol.142, No.41, 17255-17259, 2020. (Summary) DNA and RNA nucleotides are ubiquitous molecules that store and transmit genetic information. The emergence of synthetic elements that fulfill the function of DNA and RNA provides an alternative gene expression system. Herein, we demonstrate the gene expression of 4'-thioguanine DNA (dG DNA) via 4'-thiocytosine RNA (dC RNA) to give green fluorescent protein (GFPuv) in a single test tube. In replication, transcription, and translation, DNA/RNA polymerases and () ribosome can tolerate the replacement of O4' with S4' in the nucleotide, despite the fact that sulfur has a larger atomic radius than oxygen. Additionally, dG DNA and dC RNA acted as alternative genetic polymers to natural DNA and RNA for protein synthesis in artificial cells comprising a reconstituted gene expression machinery. This work involved simple experiments that are widely used in molecular biology, but which underscore the feasibility of life control by substances other than DNA/RNA nucleotides. (Keyword) Cytosine / DNA / DNA-Directed DNA Polymerase / DNA-Directed RNA Polymerases / Escherichia coli / Green Fluorescent Proteins / Protein Biosynthesis / RNA / Ribosomes / Thioguanine (Link to Publication Site) ● Publication site (DOI): 10.1021/jacs.0c07145 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33016701 ● Summary page in Scopus @ Elsevier: 2-s2.0-85092943949 (DOI: 10.1021/jacs.0c07145, PubMed: 33016701, Elsevier: Scopus)
15.	Noriko Saito-Tarashima : Chemical Approaches for RNAi Drug Development., Journal of the Pharmaceutical Society of Japan, Vol.140, No.10, 1259-1268, 2020. (Summary) RNA interference (RNAi) is the standard method of suppressing gene expression because of its target specificity, potency, and ability to silence the expression of virtually any gene. Using 21-mer small interfering RNA (siRNA) is the general approach for inducing RNAi, as siRNA can be easily prepared using a DNA/RNA synthesizer. Synthetic siRNA can be chemically modified to increase the potency of RNAi activity and abrogate innate immune stimulation. However, designing chemically modified siRNA requires substantial experimentation. A practical method for understanding the interaction of siRNA and RNAi-related proteins and how modifications affect RNA-protein interactions is therefore needed. Plasmid DNA (pDNA) expressing short hairpin RNA (shRNA) can also be used to induce RNAi. pDNA produces numerous shRNAs that induce RNAi with potent and longterm RNAi activity, even if only one pDNA molecule is delivered to the nucleus. However, this approach has some drawbacks with regard to its therapeutic application, such as a low pDNA transfection efficiency due to its huge molecular size and innate immune responses induced by extra genes, such as CpG motifs. To overcome these issues with RNAi inducers (siRNA and pDNA), our group developed some chemical approaches using chemically modified oligonucleotides. This article focuses on our two original approaches. The first involves the groove modification of siRNA duplexes to understand siRNA-protein interactions using 7-bromo-7-deazaadenosine and 3-bromo-3-deazaadenosine as chemical probes, while the second involves the generation of RNAi medicine using chemically modified DNA, known as an intelligent shRNA expression device (iRed). (Keyword) DNA / Drug Development / Immunity, Innate / Oligonucleotides / Protein Interaction Domains and Motifs / RNA Interference / RNA, Small Interfering / RNAi Therapeutics / Tubercidin (Link to Publication Site) ● Publication site (DOI): 10.1248/YAKUSHI.20-00157 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32999205 ● Summary page in Scopus @ Elsevier: 2-s2.0-85092445107 (DOI: 10.1248/YAKUSHI.20-00157, PubMed: 32999205, Elsevier: Scopus)
16.	Masashi Ohta, Noriko Saito-Tarashima and Noriaki Minakawa : フラノース環酸素原子を硫黄, セレン原子に置換した核酸誘導体の有機合成化学, Journal of Synthetic Organic Chemistry, Japan, Vol.78, No.5, 446-455, 2020. (Link to Publication Site) ● Publication site (DOI): 10.5059/yukigoseikyokaishi.78.446 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390848250110325760 ● Search Scopus @ Elsevier (DOI): 10.5059/yukigoseikyokaishi.78.446 (DOI: 10.5059/yukigoseikyokaishi.78.446, CiNii: 1390848250110325760)
17.	Hidenori ANDO, Noriko Saito-Tarashima, Lila Selim Ahmed Ali Abu Amr, Nozomi Kinjoh, Taro Shimizu, Yu Ishima, Noriaki Minakawa and Tatsuhiro Ishida : A unique gene-silencing approach, using an intelligent RNA expression device (iRed), results in minimal immune stimulation when given by local intrapleural injection in malignant pleural mesothelioma, Molecules, Vol.25, No.7, 1725, 2020. (Summary) We have recently introduced an intelligent RNA expression device (iRed), comprising the minimum essential components needed to transcribe short hairpin RNA (shRNA) in cells. Use of iRed efficiently produced shRNA molecules after transfection into cells and alleviated the innate immune stimulation following intravenous injection. To study the usefulness of iRed for local injection, the engineered iRed encoding luciferase shRNA (Luc iRed), complexed with cationic liposomes (Luc iRed/liposome-complexes), was intrapleurally injected into an orthotopic mesothelioma mouse model. Luc iRed/liposome-complexes markedly suppressed the expression of a luciferase marker gene in pleurally disseminated mesothelioma cells. The suppressive efficiency was correlated with the expression level of shRNA within the mesothelioma cells. In addition, intrapleural injection of iRed/liposome-complexes did not induce IL-6 production in the pleural space and consequently in the blood compartment, although plasmid DNA (pDNA) or dsDNA (the natural construct for iRed) in the formulation did. Local delivery of iRed could augment the in vivo gene silencing effect without eliciting pronounced innate immune stimulation. Our results might hold promise for widespread utilization of iRed as an RNAi-based therapeutic for intracelial malignant cancers. (Tokushima University Institutional Repository) ● Metadata: 115605 (Link to Publication Site) ● Publication site (DOI): 10.3390/molecules25071725 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32283709 ● Summary page in Scopus @ Elsevier: 2-s2.0-85083281974 (Tokushima University Institutional Repository: 115605, DOI: 10.3390/molecules25071725, PubMed: 32283709, Elsevier: Scopus)
18.	Kohki Matsumoto, Noriko Saito-Tarashima, Tomoya Wada, Orie Yonaha and Noriaki Minakawa : Synthesis and properties of oligonucleotides containing a 2,6-diamino-3-deazapurine:furanopyrimidine base pair, Nucleosides, Nucleotides & Nucleic Acids, 1-18, 2020. (Summary) Furanopyrimidine (FPy) and 2,6-diamino-3-deazapurine (DCPu) nucleosides with the ability to interact in DDD and AAA H-bonding patterns, respectively, were prepared. The N-1 p value of the DCPu nucleoside was estimated to be 6.4, which is due to the lack of a nitrogen atom at the 3-position, suggesting that DCPu acts as a base interacting in a DDD H-bonding pattern under near physiological conditions. As DCPu and FPy are expected to form a thermally stable DDD:AAA type of base pair in an oligodeoxynucleotide (ODN) duplex, they were incorporated into ODNs, and the value of the ODN duplex was determined. However, the ODN duplex containing a DCPu:FPy pair has a lower thermal stability than that containing a G:C pair does, although its thermal stability is equal to that of an ODN duplex with an A:T pair even under acidic conditions. (Link to Publication Site) ● Publication site (DOI): 10.1080/15257770.2019.1694687 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31994434 ● Search Scopus @ Elsevier (PMID): 31994434 ● Search Scopus @ Elsevier (DOI): 10.1080/15257770.2019.1694687 (DOI: 10.1080/15257770.2019.1694687, PubMed: 31994434)
19.	Tomoya Wada, Noriko Saito-Tarashima, Mayu Yamada, Yasuko Okamoto and Noriaki Minakawa : Synthesis of nucleoside units possessing photoreactive diazirine groups on the major and minor groove faces., Tetrahedron Letters, Vol.60, No.23, 1530-1533, 2019. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.tetlet.2019.05.008 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85065430415 (DOI: 10.1016/j.tetlet.2019.05.008, Elsevier: Scopus)
20.	Yuki Okano, Noriko Saito-Tarashima, Madoka Kurosawa, Ai Iwabu, Masashi Ohta, Tadashi Watanabe, Fumihiro Kato, Hishiki Takayuki, Masahiro Fujimuro and Noriaki Minakawa : Synthesis and biological evaluation of novel imidazole nucleosides as potential anti-dengue virus agents., Bioorganic & Medicinal Chemistry, Vol.27, No.11, 2181-2186, 2019. (Summary) In this work, we developed imidazole nucleoside derivatives with anti-dengue virus (DENV) activity was examined. First, compounds in a nucleosides library were screened to find lead compounds which inhibit replication of DENV. As a result, 5-ethynyl-(1-β-d-ribofuranosyl)imidazole-4-carboxamide (1; EICAR) and its 4-carbonitrile derivative EICNR (2) were selected as promising antiviral compounds. However, both of them also exhibited cytotoxicity. In order to develop an effective and less toxic compound, 4'-thio and 4'-seleno derivatives of EICAR and EICNR 3-6 were prepared. The resulting 4'-thioEICAR and 4'-thioEICNR showed inhibitory effect on DENV replication without cytotoxicity as potent as ribavirin, a positive control. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bmc.2019.04.015 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31003866 ● Summary page in Scopus @ Elsevier: 2-s2.0-85064318132 (DOI: 10.1016/j.bmc.2019.04.015, PubMed: 31003866, Elsevier: Scopus)
21.	Noriko Saito-Tarashima : 四本の水素結合を介してペアを形成するImNN:NaOO塩基対の複製, 日本核酸化学会誌, No.3, 17-21, 2019.
22.	Anindita D. Paulina, Sasaki Michihito, Okada Kazuma, Ito Naoto, Sugiyama Makoto, Noriko Saito-Tarashima, Noriaki Minakawa, Shuto Satoshi, Otsuguro Satoko, Ichikawa Satoshi, Matsuda Akira, Maenaka Katsumi, Orba Yasuko and Sawa Hirofumi : Ribavirin-related compounds exert in vitro inhibitory effects toward rabies virus, Antiviral Research, Vol.154, 1-9, 2018. (Summary) Rabies remains an invariably fatal neurological disease despite the availability of a preventive vaccination and post-exposure prophylaxis that must be immediately administered to the exposed individual before symptom onset. There is no effective medication for treatment during the symptomatic phase. Ribavirin, a guanine nucleoside analog, is a potent inhibitor of rabies virus (RABV) replication in vitro but lacks clinical efficacy. Therefore, we attempted to identify potential ribavirin analogs with comparable or superior anti-RABV activity. Antiviral activity and cytotoxicity of the compounds were initially examined in human neuroblastoma cells. Among the tested compounds, two exhibited a 5- to 27-fold higher anti-RABV activity than ribavirin. Examination of the anti-RABV mechanisms of action of the compounds using time-of-addition and minigenome assays revealed that they inhibited viral genome replication and transcription. Addition of exogenous guanosine to RABV-infected cells diminished the antiviral activity of the compounds, suggesting that they are involved in guanosine triphosphate (GTP) pool depletion by inhibiting inosine monophosphate dehydrogenase (IMPDH). Taken together, our findings underline the potency of nucleoside analogs as a class of antiviral compounds for the development of novel agents against RABV. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.antiviral.2018.03.011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29601893 ● Search Scopus @ Elsevier (PMID): 29601893 ● Search Scopus @ Elsevier (DOI): 10.1016/j.antiviral.2018.03.011 (DOI: 10.1016/j.antiviral.2018.03.011, PubMed: 29601893)
23.	Noriko Saito-Tarashima and Noriaki Minakawa : Unnatural base pairs for synthetic biology, Chemical & Pharmaceutical Bulletin, Vol.66, No.2, 132-138, 2018. (Summary) In this review, we have summarized the research effort into the development of unnatural base pairs beyond standard Watson-Crick (WC) base pairs for synthetic biology. Prior to introducing our research results, we present investigations by four outstanding groups in the field. Their research results demonstrate the importance of shape complementarity and stacking ability as well as hydrogen-bonding (H-bonding) patterns for unnatural base pairs. On the basis of this research background, we developed unnatural base pairs consisting of imidazo[5',4':4.5]pyrido[2,3-d]pyrimidines and 1,8-naphthyridines, i.e., Im : Na pairs. Since Im bases are recognized as ring-expanded purines and Na bases are recognized as ring-expanded pyrimidines, Im : Na pairs are expected to satisfy the criteria of shape complementarity and enhanced stacking ability. In addition, these pairs have four non-canonical H-bonds. Because of these preferable properties, ImN : NaO, one of the Im : Na pairs, is recognized as a complementary base pair in not only single nucleotide insertion, but also the PCR. (Keyword) unnatural base pair / hydrogen-bonding / shape complementarity / DNA polymerase / PCR (Link to Publication Site) ● Publication site (DOI): 10.1248/cpb.c17-00685 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29386463 ● CiNii @ National Institute of Informatics (CRID): 1390001204178944128 ● Summary page in Scopus @ Elsevier: 2-s2.0-85041595252 (DOI: 10.1248/cpb.c17-00685, PubMed: 29386463, CiNii: 1390001204178944128, Elsevier: Scopus)
24.	Noriko Saito-Tarashima, Kazuki Ishii, Masashi Ohta, 林弘也, Seigi Yamamoto and Noriaki Minakawa : 生物学的等価性に重点をおいた化学修飾核酸の創製-4'-セレノリボヌクレオシドの合成とオリゴマーへの導入-, 日本核酸医薬学会誌, Vol.21, No.1, 4-13, 2017.
25.	Yohsuke Igata, Noriko Saito-Tarashima, Daiki Matsumoto, Kazuyuki Sagara and Noriaki Minakawa : A catch and release strategy towards HPLC-free purification of synthetic oligonucleotides using a phosphoramidite unit possessing a photocleavable azide linker, Bioorganic & Medicinal Chemistry, Vol.25, No.21, 5962-5967, 2017. (Summary) A convenient strategy to purify oligonucleotides (ONs) synthesized by solid phase synthesis on an automatic DNA/RNA synthesizer was described. By attaching a photocleavable azide linker as the last phosphoramidite unit in the ON synthesis, only the desired full-length sequence was 'caught' on a controlled pore glass (CPG) resin possessing an aza-dimethoxycyclooctyne (DIBAC) derivative. Washing the resulting CPG resin to remove all unbounded species, the subsequent photoirradiation allowed the pure ONs to be 'released' without leaving any chemical modifications on native ON structure or chemical reagents from the solid phase ON synthesis. (Keyword) Alkynes / Azides / Chromatography, High Pressure Liquid / Cycloaddition Reaction / Molecular Structure / Oligonucleotides / Photochemical Processes / Ultraviolet Rays (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bmc.2017.09.014 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28986115 ● Search Scopus @ Elsevier (PMID): 28986115 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bmc.2017.09.014 (DOI: 10.1016/j.bmc.2017.09.014, PubMed: 28986115)
26.	Kazuto Shiraishi, Noriko Saito-Tarashima, Yohsuke Igata, Keiji Murakami, Yasuko Okamoto, Yoichiro Miyake, Kazuhiro Furukawa and Noriaki Minakawa : Synthesis and evaluation of c-di-4'-thioAMP as an artificial ligand for c-di-AMP riboswitch, Bioorganic & Medicinal Chemistry, Vol.25, No.14, 3883-3889, 2017. (Summary) Cyclic-di-adenosine monophosphate (c-di-AMP) is a bacterial second messenger that binds to an RNA receptor called riboswitch and regulates its downstream genes involving cell wall metabolism, ion transport, and spore germination. Therefore, the c-di-AMP riboswitch can be a novel target of antibiotics. In this study, we synthesized c-di-4'-thioAMP (1), which possesses a sulfur atom instead of an oxygen atom in the furanose ring, as a candidate of a bioisoster for natural c-di-AMP. The resulting 1 bound to the c-di-AMP riboswitch with a micromolar affinity (34.8M), and the phosphodiesterase resistance of 1 was >12-times higher than that of c-di-AMP. Thus, 1 can be considered to be a stable ligand against a c-di-AMP riboswitch. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bmc.2017.05.042 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28559057 ● Search Scopus @ Elsevier (PMID): 28559057 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bmc.2017.05.042 (DOI: 10.1016/j.bmc.2017.05.042, PubMed: 28559057)
27.	Takeo Iwata, Kyoko Kuribayashi, Masahiko Nakasono, Noriko Saito-Tarashima, Noriaki Minakawa, Noriko Mizusawa, Rie Kido and Katsuhiko Yoshimoto : The AMPK/mTOR pathway is involved in D-dopachrome tautomerase gene transcription in adipocytes differentiated from SGBS cells, a human preadipocyte cell line, Cytokine, Vol.96, 195-202, 2017. (Summary) In adipose tissue, D-dopachrome tautomerase (DDT), a cytokine with structural similarity to macrophage migration inhibitory factor, is mainly expressed in adipocytes rather than preadipocytes and acts as an anti-obesity adipokine in an autocrine manner. However, its transcriptional regulation is largely unknown. In order to explore molecules affecting DDT transcription, a chemical library screening using HEK293 cells stably expressing a DDT promoter-reporter construct was performed. Several derivatives of 5-aminoimidazole-4-carboxamide-1--d-ribofuranoside (AICAR), an AMP-activated protein kinase (AMPK) activator, were identified as transcriptional activators of the DDT gene. Furthermore, DDT mRNA levels were reduced in SGBS adipocytes treated with compound C, an AMPK inhibitor, suggesting involvement of AMPK in DDT transcription. Overexpression of the FOXO1 constitutive active form reduced transcriptional activity of the DDT gene in SGBS cells, but increased it in HEK293 cells. Cell-type specific effects were also observed in the DDT gene expression of cells treated with AS1842856, a FOXO1 inhibitor. Finally, involvement of the mammalian target of rapamycin (mTOR) signaling in DDT transcription in SGBS adipocytes was investigated. Rapamycin, an inhibitor of mTOR, increased DDT mRNA levels and attenuated the inhibitory effects of compound C on DDT mRNA levels in SGBS adipocytes. In conclusion, DDT transcription may be regulated in a cell-dependent manner, and were enhanced by AMPK activation in SGBS adipocytes through inhibiting the mTOR signaling. (Tokushima University Institutional Repository) ● Metadata: 111466 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.cyto.2017.04.017 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28445821 ● Summary page in Scopus @ Elsevier: 2-s2.0-85018474373 (Tokushima University Institutional Repository: 111466, DOI: 10.1016/j.cyto.2017.04.017, PubMed: 28445821, Elsevier: Scopus)
28.	Noriko Saito-Tarashima, Masashi Ohta and Noriaki Minakawa : Synthesis of 4'-selenoribonucleosides, the building blocks of 4'-selenoRNA, using a hypervalent iodine., Current Protocols in Nucleic Acid Chemistry, Vol.70, 1.40.1-21, 2017. (Summary) Herein is described a detailed protocol for the synthesis of 4'-selenoribonucleoside derivatives that involves the use of a hypervalent iodine species. These derivatives are versatile units for the preparation of 4'-selenoRNA. Large-scale synthesis of a 4-selenosugar starting from D-ribose is achieved in eight steps, including a final chromatographic purification. The resulting 4-selenosugar is then subjected to the one-pot Pummerer-like reaction using hypervalent iodine in the presence of silylated nucleobases. The reaction with silylated uracil affords the desired 4'-selenouridine derivatives with excellent -selectivity and in good yield. Conversely, when purine nucleobases are used in the Pummerer-like reaction, N7 4'-selenoribonucleoside isomers are obtained alongside the desired N9 isomers. However, the undesired N7 isomers can be converted to the desired N9 ones under acidic conditions. © 2017 by John Wiley & Sons, Inc. (Link to Publication Site) ● Publication site (DOI): 10.1002/cpnc.34 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28921498 ● Search Scopus @ Elsevier (PMID): 28921498 ● Search Scopus @ Elsevier (DOI): 10.1002/cpnc.34 (DOI: 10.1002/cpnc.34, PubMed: 28921498)
29.	Kazuki Ishii, Noriko Saito-Tarashima, Masashi Ota, Seigi Yamamoto, Yasuko Okamoto, Yoshiyuki Tanaka and Noriaki Minakawa : Practical synthesis of 4'-selenopurine nucleosides by combining chlorinated purines and 'armed' 4'-selenosugar, Tetrahedron, Vol.72, No.41, 6589-6594, 2016. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.tet.2016.08.071 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.tet.2016.08.071 (DOI: 10.1016/j.tet.2016.08.071)
30.	Noriko Saito-Tarashima, Hirotaka Kira, Tomoya Wada, Kazuya Miki, Shiho Ide, Naoshi Yamazaki, Akira Matsuda and Noriaki Minakawa : Groove modification of siRNA duplexes to elucidate siRNA-protein interactions using 7-bromo-7-deazaadenosine and 3-bromo-3-deazaadenosine as chemical probes, Organic & Biomolecular Chemistry, Vol.14, No.47, 11096-11105, 2016. (Summary) Elucidation of dynamic interactions between RNA and proteins is essential for understanding the biological processes regulated by RNA, such as RNA interference (RNAi). In this study, the logical chemical probes, comprising 7-bromo-7-deazaadenosine (Br(7)C(7)A) and 3-bromo-3-deazaadenosine (Br(3)C(3)A), to investigate small interfering RNA (siRNA)-RNAi related protein interactions, were developed. The bromo substituents of Br(7)C(7)A and Br(3)C(3)A are expected to be located in the major and the minor grooves, respectively, and to act as a steric hindrance in each groove when these chemical probes are incorporated into siRNAs. A comprehensive investigation using siRNAs containing these chemical probes revealed that (i) Br(3)C(3)A(s) at the 5'-end of the passenger strand enhanced their RNAi activity, and (ii) the direction of RISC assembly is determined by the interaction between Argonaute2, which is the main component of RISC, and siRNA in the minor groove near the 5'-end of the passenger strand. Utilization of these chemical probes enables the investigation of the dynamic interactions between RNA and proteins. (Link to Publication Site) ● Publication site (DOI): 10.1039/c6ob01866a (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27714245 ● Summary page in Scopus @ Elsevier: 2-s2.0-84999752038 (DOI: 10.1039/c6ob01866a, PubMed: 27714245, Elsevier: Scopus)
31.	Mahadi Hasan, Noriko Saito-Tarashima, Koki Fujikawa, Takashi Ohgita, Susumu Hama, Tamotsu Tanaka, Hiroyuki Saito, Noriaki Minakawa and Kentaro Kogure : The novel functional nucleic acid iRed effectively regulates target genes following cytoplasmic delivery by faint electric treatment, Science and Technology of Advanced Materials, Vol.17, No.17, 554-562, 2016. (Summary) An intelligent shRNA expression device (iRed) contains the minimum essential components needed for shRNA production in cells, and could be a novel tool to regulate target genes. However, general delivery carriers consisting of cationic polymers/lipids could impede function of a newly generated shRNA via electrostatic interaction in the cytoplasm. Recently, we found that faint electric treatment (fET) of cells enhanced delivery of siRNA and functional nucleic acids into the cytoplasm in the absence of delivery carriers. Here, we examined fET of cells stably expressing luciferase in the presence of iRed encoding anti-luciferase shRNA. Transfection of lipofectamine 2000 (LFN)/iRed lipoplexes showed an RNAi effect, but fET-mediated iRed transfection did not, likely because of the endosomal localization of iRed after delivery. However, fET in the presence of lysosomotropic agent chloroquine significantly improved the RNAi effect of iRed/fET to levels that were higher than those for the LFN/iRed lipoplexes. Furthermore, the amount of lipid droplets in adipocytes significantly decreased following fET with iRed against resistin in the presence of chloroquine. Thus, iRed could be a useful tool to regulate target genes following fET-mediated cytoplasmic delivery with endosomal escape devices. (Tokushima University Institutional Repository) ● Metadata: 115720 (Link to Publication Site) ● Publication site (DOI): 10.1080/14686996.2016.1221726 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27877903 ● Summary page in Scopus @ Elsevier: 2-s2.0-85019070861 (Tokushima University Institutional Repository: 115720, DOI: 10.1080/14686996.2016.1221726, PubMed: 27877903, Elsevier: Scopus)
32.	Noriko Saito-Tarashima, Hidenori ANDO, Takamitsu Kojima, Nozomi Kinjo, Yosuke Hashimoto, Kazuhiro Furukawa, Tatsuhiro Ishida and Noriaki Minakawa : Gene silencing using 4'-thioDNA as an artificial template to synthesize short-hairpin RNA without inducing a detectable innate immune response, Molecular Therapy. Nucleic Acids, Vol.5, e274, 2016. (Summary) The development of a versatile technique to induce RNA interference (RNAi) without immune stimulation in vivo is of interest as existing approaches to trigger RNAi, such as small interfering RNA (siRNA) and plasmid DNA (pDNA) expressing short hairpin RNA (shRNA), present drawbacks arising from innate immune stimulation. To overcome them, an intelligent shRNA expression device (iRed) designed to induce RNAi was developed. The minimum sequence of iRed encodes only the U6 promoter and shRNA. A series of iRed comprises a polymerase chain reaction (PCR)-amplified 4'-thioDNA in which any one type of adenine (A), guanine (G), cytosine (C), or thymine (T) nucleotide unit was substituted by each cognate 4'-thio derivatives, i.e., dSA iRed, dSG iRed, dSC iRed, and ST iRed respectively. Each modified iRed acted as a template to transcribe shRNA with RNAi activity. The highest shRNA yield was generated using dSC iRed that exerted gene silencing activity in an orthotopic mouse model of mesothelioma. Reducing the minimal structure required to transcribe shRNA and the presence of the 4'-thiomodification synergistically function to abrogate innate immune response induced by dsDNA. The iRed will introduce a new approach to induce RNAi without inducing a detectable innate immune response. (Tokushima University Institutional Repository) ● Metadata: 110894 (Link to Publication Site) ● Publication site (DOI): 10.1038/mtna.2015.48 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26730811 ● Summary page in Scopus @ Elsevier: 2-s2.0-84953792236 (Tokushima University Institutional Repository: 110894, DOI: 10.1038/mtna.2015.48, PubMed: 26730811, Elsevier: Scopus)
33.	Noriko Saito-Tarashima, Komatsu Yasuo, Kazuhiro Furukawa and Noriaki Minakawa : Faithful PCR Amplification of an Unnatural Base-Pair Analogue with Four Hydrogen Bond, Chemistry - A European Journal, Vol.21, No.30, 10688-10695, 2015. (Summary) In vitro replication of an unnatural imidazopyridopyridine:naphthyridine base pair, (i.e., ImN(N):NaO(O)), having four hydrogen bonds was investigated. Kinetic studies of single-nucleotide insertion revealed that ImN(N) and NaO(O) were recognized as complementary bases by an exonuclease-deficient Klenow fragment with higher specificity and efficiency than two previously described pairs (ImN(O):NaO(N) and ImO(N):NaN(O)) because of higher thermal and thermodynamic stabilities and the DAAD:ADDA (D=donor, A=acceptor) hydrogen-bonding pattern of the ImN(N):NaO(O) pair. Faithful polymerase chain reaction (PCR) amplification of a DNA fragment containing the ImN(N):NaO(O) pair was achieved by using DNA polymerases possessing 3'5' exonuclease activity (99.5 % per doubling). (Keyword) Base Pairing / Base Sequence / DNA / DNA Polymerase I / Hydrogen Bonding / Imidazoles / Kinetics / Models, Molecular / Naphthyridines / Polymerase Chain Reaction / Pyridines / Thermodynamics (Link to Publication Site) ● Publication site (DOI): 10.1002/chem.201501484 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26177045 ● Summary page in Scopus @ Elsevier: 2-s2.0-84937002817 (DOI: 10.1002/chem.201501484, PubMed: 26177045, Elsevier: Scopus)
34.	Noriko Saito-Tarashima, Tatsuya Sumitomo, Hidenori ANDO, Kazuhiro Furukawa, Tatsuhiro Ishida and Noriaki Minakawa : Synthesis of DNA fragments containing 2-deoxy-4-selenonucleoside units using DNA polymerases: comparison of dNTPs with O, S and Se at the 4-position in replication Org, Organic & Biomolecular Chemistry, Vol.13, No.25, 6949-6952, 2015. (Summary) 4'-SelenoDNA fragments were synthesized for the first time using 4'-selenothymidine triphosphate (SeTTP) by taking advantage of its bioequivalence against DNA polymerases. DNA fragments each with a homologous element (O, S or Se) at the 4'-position of the thymidine units were effectively amplified using KOD Dash DNA polymerase. (Link to Publication Site) ● Publication site (DOI): 10.1039/c5ob00941c (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26053864 ● Summary page in Scopus @ Elsevier: 2-s2.0-84934957265 (DOI: 10.1039/c5ob00941c, PubMed: 26053864, Elsevier: Scopus)
35.	Yota Saito, Yosuke Hashimoto, Mai Arai, Noriko Saito-Tarashima, Tadashi Miyazawa, Kazuya Miki, Mayumi Takahashi, Kazuhiro Furukawa, Naoshi Yamazaki, Akira Matsuda, Tatsuhiro Ishida and Noriaki Minakawa : Chemistry, properties, and in vitro and in vivo applications of 2'-O-methoxyethyl-4'-thioRNA, a novel hybrid type of chemically modified RNA., ChemBioChem, Vol.15, No.17, 2535-2540, 2014. (Summary) We report the synthesis, properties, and in vitro and in vivo applications of 2'-O-methoxyethyl-4'-thioRNA (MOE-SRNA), a novel type of hybrid chemically modified RNA. In its hybridization with complementary RNA, MOE-SRNA showed a moderate improvement of Tm value (+3.4 °C relative to an RNA:RNA duplex). However, the results of a comprehensive comparison of the nuclease stability of MOE-SRNA relative to 2'-O-methoxyethylRNA (MOERNA), 2'-O-methyl-4'-thioRNA (Me-SRNA), 2'-O-methylRNA (MeRNA), 4'-thioRNA (SRNA), and natural RNA revealed that MOE-SRNA had the highest stability (t1/2 >48 h in human plasma). Because of the favorable properties of MOE-SRNA, we evaluated its in vitro and in vivo potencies as an anti-microRNA oligonucleotide against miR-21. Although the in vitro potency of MOE-SRNA was moderate, its in vivo potency was significant for the suppression of tumor growth (similar to that of MOERNA). (Keyword) Animals / Cell Proliferation / HeLa Cells / Humans / Mice / Mice, Inbred BALB C / Mice, Nude / MicroRNAs / Neoplasms / Nucleic Acid Conformation / RNA / RNA Stability / Tumor Cells, Cultured (Link to Publication Site) ● Publication site (DOI): 10.1002/cbic.201402398 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25314258 ● Summary page in Scopus @ Elsevier: 2-s2.0-84915745333 (DOI: 10.1002/cbic.201402398, PubMed: 25314258, Elsevier: Scopus)
36.	Noriko Saito-Tarashima, Koya Hayashi, Maki Terasaki, Hirotsugu Taniike, Yusuke Inagaki, Kenji Hirose, Kazuhiro Furukawa, Akira Matsuda and Noriaki Minakawa : First Synthesis of Fully Modified 4-SelenoRNA and 2-OMe-4-selenoRNA Based on the Mechanistic Considerations of an Unexpected Strand Break, Organic Letters, Vol.16, No.18, 4710-4713, 2014. (Summary) This study investigated oligonucleotide (ON) synthesis containing 4'-selenoribonucleoside(s) under standard phosphoramidite conditions. Careful operation using a manual ON synthetic system revealed that an unexpected strand break occurred to afford a C2-symmetric homodimer as a byproduct. In addition, this side reaction occurred during I2 oxidation. On the basis of these findings, the first synthesis of fully modified 4'-selenoRNA and 2'-OMe-4'-selenoRNA was achieved using tert-butyl hydroperoxide (TBHP) as the alternative oxidant. (Link to Publication Site) ● Publication site (DOI): 10.1021/ol502077h (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25181546 ● Summary page in Scopus @ Elsevier: 2-s2.0-84927589726 (DOI: 10.1021/ol502077h, PubMed: 25181546, Elsevier: Scopus)

Review, Commentary:

1.	Noriko Saito-Tarashima, KINOSHITA Mao, Yohsuke Igata, Kazuto Shiraishi, Kazuhiro Furukawa and Noriaki Minakawa : 4'-チオRNAにより構成される環状ジヌクレオチドアナログの創製, 日本ケミカルバイオロジー学会誌, Vol.15, May 2022.

Proceeding of International Conference:

1.	Noriko Saito-Tarashima : Chemical biology and medicinal chemistry of cyclic dinucleotides, 日本薬学会第144年会, Mar. 2024.
2.	Noriaki Minakawa, Noriko Saito-Tarashima, Takaaki Koma, NAOTO Hinotani, YOSHIDA Keigo, OGASA Moka, AKIHO Murai, INOUE Shuya, Tomoyuki Kondo, Naoya Doi, Koichi Tsuneyama and Masako Nomaguchi : 3-Deazaguanosine exhibits anti-SARS-CoV-2 activity and blocks the development of COVID-19 pneumonis in hamsters., Supra FIBER International Summit for Nucleic Acids (S-FISNA) 2024, Mar. 2024.
3.	AKIHO Murai, Noriko Saito-Tarashima, OBA Mizuki, Kanako Kawanishi, Jun Tsukimoto and Noriaki Minakawa : Disruption of the cell membrane by G-quadruplex formation on antibody, Supra FIBER International Summit for Nucleic Acids (S-FISNA) 2024, Mar. 2024.
4.	Nogi Yuhei, Noriko Saito-Tarashima, Takaaki Koma, Masako Nomaguchi and Noriaki Minakawa : Development of the 4'-thiomodified siRNAs against SARS-CoV-2, 14th AFMC International Medicinal Chemistry Symposium, Jun. 2023.
5.	Noriko Saito-Tarashima and Noriaki Minakawa : Chemical challenge to the central dogma with 4-thionucleotides, 15h International Symposium on Nanomedicine (ISNM2022), Dec. 2022.
6.	Shunya Yamauchi, Noriko Saito-Tarashima, Kou Motani, Hidetaka Kosako and Noriaki Minakawa : Synthesis of cyclic dinucleotide analog enhanced membrane permeability, 15h International Symposium on Nanomedicine (ISNM2022), Dec. 2022.
7.	YUTA Kashiwabara, Shunya Yamauchi, Noriko Saito-Tarashima and Noriaki Minakawa : Synthesis of the membrane-permeable 2,3-cGAMP type CDN analog, 15h International Symposium on Nanomedicine (ISNM2022), Dec. 2022.
8.	YUHEI Nogi, Noriko Saito-Tarashima and Noriaki Minakawa : Synthesis and evaluation of the DNA oligomer possessing 5-aminoimidazole-4-carboxamide (Z)-base, 15h International Symposium on Nanomedicine (ISNM2022), Dec. 2022.
9.	YUHEI Nogi, Noriko Saito-Tarashima and Noriaki Minakawa : Synthesis and physical/enzymatic behaviors of the DNA oligomer possessing an ambiguous base, 5-aminoimidazole-4-carboxamide, The 49th International Symposium on Nucleic Acids Chemistry / The 6th Annual Meeting of Japan Society of Nucleic Acids Chemistry (ISNAC2022), Nov. 2022.
10.	Mao Kinoshita, Noriko Saito-Tarashima and Noriaki Minakawa : Synthesis of 4'-thiomodified cyclic dinucleotide analogs as STING agonists, AFMC International Medicinal Chemistry Symposium 2021 (AIMECS2021), Nov. 2021.
11.	Noriko Saito-Tarashima, Ayako Matsuo and Noriaki Minakawa : Transmission of the genetic information from 4-thioDNA to 4-thioRNA to protein, The 48th International Symposium on Nucleic Acids Chemistry / The 5th Annual Meeting of Japan Society of Nucleic Acids Chemistry (ISNAC2021), Nov. 2021.
12.	Mao Kinoshita, Noriko Saito-Tarashima and Noriaki Minakawa : Chemical synthesis and evaluation of 4'-thiomodified cyclic dinucleotides, The 48th International Symposium on Nucleic Acids Chemistry / The 5th Annual Meeting of Japan Society of Nucleic Acids Chemistry (ISNAC2021), Nov. 2021.
13.	Toshiki Miyazawa, Rion Maeda, Noriko Saito-Tarashima, Yuichi Yoshimura and Noriaki Minakawa : Synthesis and Properties of 4'-ThioLNA/BNA, The 48th International Symposium on Nucleic Acids Chemistry / The 5th Annual Meeting of Japan Society of Nucleic Acids Chemistry (ISNAC2021), Nov. 2021.
14.	Yusuke Kumanomidoh, Noriko Saito-Tarashima and Noriaki Minakawa : Synthesis of cyclic-di-ZMP, The 46th International Symposium on Nucleic Acids Chemistry / The 3rd Annual Meeting of Japan Society of Nucleic Acids Chemistry (ISNAC 2019), Oct. 2019.
15.	Noriko Saito-Tarashima, Yusuke Kumanomidoh, Mao Kinoshita, Kazuto Shiraishi, Kazuhiro Furukawa and Noriaki Minakawa : Synthesis and biological evaluation of cyclic dinucleotide analogs., Commemorative International Symposium of the Japan Society of Nucleic Acids Chemistry (CISNAC 2019), Jul. 2019.
16.	Noriko Saito-Tarashima and Noriaki Minakawa : Synthesis and biological potential of modified cyclic dinucleotides., Asian International Symposium, Mar. 2019.
17.	Seigi Yamamoto, Noriko Saito-Tarashima, Naoshi Yamazaki, Tatsuya Fukuta, Kentaro Kogure and Noriaki Minakawa : Development and Evaluation of Photoresponsive DNA Prism with Nucleic Acid Medicine., The 45th International Symposium on Nucleic Acids Chemistry (ISNAC 2018), Nov. 2018.
18.	Kohki Matsumoto, Noriko Saito-Tarashima and Noriaki Minakawa : Creation of a puDDD: pyAAA H-bonding base pair in DNA oligonucleotide., The 45th International Symposium on Nucleic Acids Chemistry (ISNAC 2018), Nov. 2018.
19.	Tomoya Wada, Mayu Yamada, Noriko Saito-Tarashima and Noriaki Minakawa : Elucidating dynamic interactions between siRNA and proteins using a pair of nucleoside chemical probes., The 23rd International Roundtable of Nucleosides,Nucleotides and Nucleic Acids(IRT 2018), Aug. 2018.
20.	Seigi Yamamoto, Noriko Saito-Tarashima and Noriaki Minakawa : Development of Photoresponsive DNA Nanostructure Integrated Nucleic Acid Medicine, The 44th International Symposium on Nucleic Acids Chemistry (ISNAC 2017), Nov. 2017.
21.	Masashi Ohta, Noriko Saito-Tarashima and Noriaki Minakawa : Synthesis and properties of 4-selenoRNA, The 44th International Symposium on Nucleic Acids Chemistry (ISNAC 2017), Nov. 2017.
22.	Kentaro Kogure, Noriko Saito-Tarashima, K Fujikawa, Y Oshima, Tasuku Torao, M Mimura, M Hasan, S Hama, Tamotsu Tanaka, Hiroyuki Saito and Noriaki Minakawa : Effective cellular delivery of intelligent shRNA expression device by faint electricity., The 5th Seminar of pharmaceutial sciences and technology., Sep. 2017.
23.	Kentaro Kogure, Noriko Saito-Tarashima, K Fujikawa, Y Oshima, Tasuku Torao, M Mimura, M Hasan, S Hama, Tamotsu Tanaka, Hiroyuki Saito and Noriaki Minakawa : Effective cellular delivery of intelligent shRNA expression device by faint electricity., 6th FIP Pharmaceutical Sciences World Congress (PSWC), May 2017.
24.	Noriko Saito-Tarashima, Koya Hayashi, Tatsuya Sumitomo and Noriaki Minakawa : Chemical and enzymatic synthesis of 4'-seleno oligonucleotides, ISNAC 2016 (The 43th International Symposium on Nucleic Acids Chemistry), Sep. 2016.
25.	Noriko Saito-Tarashima and Noriaki Minakawa : Generation of RNA medicine using 4-thio DNA, The 8th Takeda Science Foundation Symposium on PharmaSciences, Osaka, Jan. 2016.
26.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Targeted gene silencing by introduction of intelligent RNA expression device (iRed), Liposome Advances 2015, London, Dec. 2015.
27.	Noriaki Minakawa and Noriko Saito-Tarashima : Efficient preparation of a dumbbell-shaped minimal vector for short hairpin RNA expression using on unnatural base pair system, 3rd International Symposium on Nanomedicine Molecular Science, Tokyo, Nov. 2015.
28.	Noriko Saito-Tarashima and Noriaki Minakawa : Development of a Minimally-Sized DNA Vector for Gene Silencing using an Unnatural Base Pair Analog Having Four Hydrogen Bonds, AIMECS 2015(10th AFMC International Medicinal Chemistry Symposium in 2015), JEJU(Korea), Oct. 2015.
29.	Noriko Saito-Tarashima, Kinjo Nozomi, Kojima Takamitsu, Hidenori ANDO, Tatsuhiro Ishida and Noriaki Minakawa : Gene silencing via RNA interference (RNAi) machinery using 4'-thioDNA as an artificial template, The 42nd International Symposium on Nucleic Acids Chemistry, Himeji, Sep. 2015.
30.	Miyazawa Tadashi, Noriko Saito-Tarashima, Kazuhiro Furukawa and Noriaki Minakawa : Synthesis and Properties of a novel 1,2-dithianenucleoside, The 41st International Symposium on Nucleic Acids Chemistry, Kitakyushu International Conference Center(Kitakyusyu Japan), Nov. 2014.
31.	Sagara Kazuyuki, Noriko Saito-Tarashima, Kazuhiro Furukawa and Noriaki Minakawa : A convenient RNA purification method with a combination of click chemistry and a photolabile group, The 41st International Symposium on Nucleic Acids Chemistry, Kitakyushu International Conference Center(Kitakyusyu Japan), Nov. 2014.
32.	Noriko Saito-Tarashima, Sumitomo Tatsuya, Kazuhiro Furukawa and Noriaki Minakawa : ENZYMATIC SYNTHESIS OF 4-SELENODNA, XXI Round Table on Nucleosides, Nucleotides and Nucleic Acids, Poznan(Poland), Aug. 2014.
33.	Noriaki Minakawa, Noriko Saito-Tarashima, Hayashi Koya, Terasaki Maki, Taniike Hirotsugu, Inagaki Yusuke, Fukuda Shinji, Kazuhiro Furukawa and Matsuda Akira : How to prepare 4-selenoRNA?, XXI Round Table on Nucleosides, Nucleotides and Nucleic Acids, Poznan(Poland), Aug. 2014.
34.	Noriko Saito-Tarashima, Kojima Takamitsu, Hashimoto Yosuke, Kazuhiro Furukawa, Naoshi Yamazaki, Hiroshi Kiwada, Tatsuhiro Ishida, Noriaki Minakawa and Yoshiharu Takiguchi : A novel approach of gene suppression using an intelligent shRNA expressing device (iRed), 9th Annual Meeting of the Oligonucleotide Therapeutics Society, Naples(Italy), Oct. 2013.

Proceeding of Domestic Conference:

1.	Yuki Sakaue, Noriko Saito-Tarashima and Noriaki Minakawa : 2'-Fluoro-4'-thioRNAの開発研究, 2024年度第1回 (35回) 日本プロセス学会東四国地区フォーラムセミナー, Jun. 2024.
2.	OGASA Moka, YOSHIDA Keigo, INOUE Shuya, NAOTO Hinotani, AKIHO Murai, Noriko Saito-Tarashima and Noriaki Minakawa : 抗SARS-CoV2活性を示すヌクレオシドアナログの設計・合成と活性評価, 2024年度第1回 (35回) 日本プロセス学会東四国地区フォーラムセミナー, Jun. 2024.
3.	Jun Tsukimoto, RIN Fukuike, Mizuki Miyoshi, Yuto Horii, Toshiki Iniwa, Nijiho Kamori, Yoshie Takeuchi, 西岡宗一郎, Noriko Saito-Tarashima, Noriaki Minakawa and Kouji Itou : NEU1欠損症モデルマウスの作製と新規遺伝子治療法開発, 日本薬学会第144年会, Mar. 2024.
4.	Nana Mihara, Noriko Saito-Tarashima and Noriaki Minakawa : ホスホフロリダート交換反応を基盤とするDNA化学合成の検討, 日本薬学会第144年会, Mar. 2024.
5.	Noriko Saito-Tarashima : 化学で創造する遺伝情報伝達システムとその創薬応用, 日本薬学会第144年会, Mar. 2024.
6.	OBA Mizuki, AKIHO Murai, Noriko Saito-Tarashima, Jun Tsukimoto and Noriaki Minakawa : Antibody-Ologonucleotide Conjugate (AOC)を利用する光応答性抗体凝集法の開発, 日本薬学会第144年会, Mar. 2024.
7.	INOUE Taketo, Noriko Saito-Tarashima, Shintaro Inoue, Sumihare Noji, Taro Mito and Noriaki Minakawa : フタホシコオロギを用いたsiRNAのin vivo活性評価系の検討, 日本薬学会第144年会, Mar. 2024.
8.	YOSHIDA Keigo, NAOTO Hinotani, OGASA Moka, Noriko Saito-Tarashima, Takaaki Koma, Masako Nomaguchi and Noriaki Minakawa : SARS-CoV-2活性を発揮する3-デアザグアノシンの発見と作用メカニズム解明, 日本薬学会第144年会, Mar. 2024.
9.	KURODA Chihiro, YUTA Kashiwabara, Jun Tsukimoto, Noriko Saito-Tarashima and Noriaki Minakawa : 4'-チオヌクレオチドの導入による化学修飾mRNAの開発, 日本薬学会第144年会, Mar. 2024.
10.	YUHEI Nogi, Noriko Saito-Tarashima, Takaaki Koma, Jun Tsukimoto, Masako Nomaguchi and Noriaki Minakawa : 抗SARS-CoV-2活性を指標とした4'-チオ修飾siRNAの最適化, 日本薬学会第144年会, Mar. 2024.
11.	Noriko Saito-Tarashima : 化学の力で遺伝子(DNA・RNA)を創る, 第13回なでしこScientistトーク(FIBER未来大学 FIBER FUTURE COLLEGE), Jan. 2024.
12.	Noriko Saito-Tarashima : 抗ウイルス剤の開発を指向した小さな核酸創薬化学術, 徳島大学大学院医歯薬学研究部DDS研究センター徳島大学研究クラスター「次世代DDS拠点形成」 SDGs推進に係る連携創出の場形成支援事業合同シンポジウム, Dec. 2023.
13.	YUHEI Nogi, Noriko Saito-Tarashima, Takaaki Koma, Masako Nomaguchi and Noriaki Minakawa : 4'-チオ核酸修飾siRNAの開発 (1), 第62回日本薬学会·日本薬剤師会·日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
14.	Rina Ozaki, YUHEI Nogi, Noriko Saito-Tarashima, Takaaki Koma, Jun Tsukimoto, Masako Nomaguchi and Noriaki Minakawa : 4'-チオ核酸修飾siRNAの開発 (2), 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
15.	OGASA Moka, NAOTO Hinotani, Noriko Saito-Tarashima, Takaaki Koma, Masako Nomaguchi and Noriaki Minakawa : 抗SARS-CoV-2の活性獲得を目指した3-デアザプリンヌクレオシド類の合成, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
16.	Nana Mihara, Noriko Saito-Tarashima and Noriaki Minakawa : 4'-チオレムデシビルの合成研究, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
17.	KAWAGUCHI Mana, Mayu Yamada, Noriko Saito-Tarashima and Noriaki Minakawa : 抗SARS-CoV-2活性を有する5-hydroxymethyltubercidin (HMTU) の合成, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
18.	Noriko Saito-Tarashima : セントラルドグマを化学する創薬化学研究 –新モダリティ医薬品時代の薬学教育–, 第8回日本薬学教育学会大会, Aug. 2023.
19.	Jun Tsukimoto, Mizuki Miyoshi, RIN Fukuike, Yuto Horii, Nijiho Kamori, Yoshie Takeuchi, Noriko Saito-Tarashima, Noriaki Minakawa and Kouji Itou : ノイラミニダーゼ1細胞内結晶化の抑制とリソソーム病遺伝子治療への応用, 日本核酸医薬学会第8回年会, Jul. 2023.
20.	YUHEI Nogi, Noriko Saito-Tarashima, Takaaki Koma, Masako Nomaguchi and Noriaki Minakawa : SARS-CoV-2を標的とした4'-チオ修飾siRNAの創製, 日本核酸医薬学会第8回年会, Jul. 2023.
21.	Yuki Sakaue, Noriko Saito-Tarashima and Noriaki Minakawa : 2′-Fluoro-4′-thiopurine nucleosides の合成研究, 創薬懇話会2023, Jun. 2023.
22.	Kou Motani, Noriko Saito-Tarashima, 西野耕平, Shunya Yamauchi, Noriaki Minakawa and Hidetaka Kosako : 自然免疫分子STINGのオルガネラ間移行を駆動する小胞体ーゴルジ体コンタクトサイト形成因子の同定, 第75回日本細胞生物学会, Jun. 2023.
23.	HASHIMOTO Ayaka, Mai Inagaki, Noriko Saito-Tarashima, Shunya Yamauchi, Noriaki Minakawa and Masanori Tachikawa : 環状ジヌクレオチドによるヒト脳微小血管内皮細胞STING経路の活性化, 日本薬学会第143年会, Mar. 2023.
24.	YUHEI Nogi, Noriko Saito-Tarashima and Noriaki Minakawa : DNA二重らせん中におけるZ塩基の塩基対形成能, 日本薬学会第143年会, Mar. 2023.
25.	Aki Kondoh, KINOSHITA Mao, Noriko Saito-Tarashima and Noriaki Minakawa : 糖部4'位を硫黄原子で置換した環状ジヌクレオチド類 (CDNs) は優れたSTINGアゴニスト活性を発揮する, 日本薬学会第143年会, Mar. 2023.
26.	Aki Kondoh, KINOSHITA Mao, Noriko Saito-Tarashima and Noriaki Minakawa : 糖部フラノース環4'位に硫黄原子を有するcyclic dinucleotide (CDN) analogsの創薬化学研究, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
27.	Kanako Kawanishi, Noriko Saito-Tarashima and Noriaki Minakawa : 光分解性保護基を有するAntibody-Oligonucleotide Conjugateの創製, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
28.	Naoya Ueda, Noriko Saito-Tarashima and Noriaki Minakawa : 2'-置換-N4-ヒドロキシシチジン (NHC) 誘導体の合成および新型コロナウイルス (SARS-CoV-2) に対する活性評価, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
29.	AKIHO Murai, Noriko Saito-Tarashima and Noriaki Minakawa : ZTPの化学合成とRNAポリメラーゼに対する基質認識能の評価, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
30.	Yuya Shiraki, 前田璃音, MIYAZAWA Toshiki, Noriko Saito-Tarashima, 吉村祐一 and Noriaki Minakawa : 4'-チオBNA/LNAヌクレオシドの合成研究, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
31.	Yuki Sakaue, Noriko Saito-Tarashima and Noriaki Minakawa : 2'-Deoxy-2'-F-4'-thionucleosideの合成研究, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
32.	Yuma Kagotani, Noriko Saito-Tarashima and Noriaki Minakawa : 4'-SelenoRNAから構成される環状ジヌクレオチドの合成研究, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
33.	Kou Motani, Noriko Saito-Tarashima, K Nishino, Shunya Yamauchi, Noriaki Minakawa and Hidetaka Kosako : ACBD3 forms specialized ER-Golgi contact sites to drive the ER exit of STING., The 17th International Symposium of the Institute Network, Kanazawa, Oct. 2022.
34.	Shunya Yamauchi, Noriko Saito-Tarashima, Kou Motani, Hidetaka Kosako and Noriaki Minakawa : 膜透過性型cyclic dinucleotide analogの創製, 日本核酸医薬学会第7回年会, Jul. 2022.
35.	Noriko Saito-Tarashima : 環状ジヌクレオチド類のメディシナルケミストリー, 第146回日本薬学会中国四国支部例会, Jun. 2022.
36.	NAOTO Hinotani, Motoki Nakamura, Noriko Saito-Tarashima, 大場靖子, 澤洋文, 松田彰, 前仲勝美 and Noriaki Minakawa : 5-Ethynylimidazole-4-carboxamide (EICA)ヌクレオチドプロドラッグの合成と抗デングウイルス活性, 日本薬学会第142年会, Mar. 2022.
37.	Shunya Yamauchi, Noriko Saito-Tarashima, Kou Motani, Hidetaka Kosako and Noriaki Minakawa : 膜透過型STINGアゴニストとしてのbis-pivSATE-2'-F-c-di-dAMPの創製, 日本薬学会第142年会, Mar. 2022.
38.	AKIHO Murai, Noriko Saito-Tarashima and Noriaki Minakawa : ZTPの合成と各種ポリメラーゼに対する基質認識能の評価, 日本薬学会第142年会, Mar. 2022.
39.	Noriko Saito-Tarashima, KINOSHITA Mao, Aki Kondoh and Noriaki Minakawa : 環状ジヌクレオチド糖部4'位への硫黄原子の導入はSTINGアゴニスト活性を増強させる, 日本化学会第102春季年会, Mar. 2022.
40.	YUHEI Nogi, Noriko Saito-Tarashima and Noriaki Minakawa : AICA (Z) 塩基を含むDNAオリゴマーの合成と性質評価, 日本化学会第102春季年会, Mar. 2022.
41.	YUTA Kashiwabara, Shunya Yamauchi, Noriko Saito-Tarashima and Noriaki Minakawa : 膜透過型STINGアゴニストの創製研究, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
42.	YUHEI Nogi, Noriko Saito-Tarashima and Noriaki Minakawa : Z塩基を含むDNAオリゴマーの合成と物理化学的性質評価, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
43.	AKIHO Murai, Noriko Saito-Tarashima and Noriaki Minakawa : ZTPの合成とRNAポリメラーゼに対する基質認識能の解析, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
44.	NAOTO Hinotani, Noriko Saito-Tarashima and Noriaki Minakawa : 抗ウイルス活性の獲得を目指した3-デアザプリンヌクレオシド類の合成研究, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
45.	Ayuka Shibayama, Noriko Saito-Tarashima and Noriaki Minakawa : 抗RNAウイルス剤開発を目的とした5-置換ウリジン誘導体の合成, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
46.	KINOSHITA Mao, Noriko Saito-Tarashima, Aki Kondoh and Noriaki Minakawa : ヌクレオチド糖部4'位に硫黄原子を有する環状ジヌクレオチドアナログの創製, 第15回バイオ関連化学シンポジウム, Sep. 2021.
47.	Noriko Saito-Tarashima, 松尾礼子 and Noriaki Minakawa : The gene expression of 4'-thioDNA via 4'-thioRNA in an artificial cell, FIBER 核酸化学若手フォーラム, Aug. 2021.
48.	UENO Mana, Noriko Saito-Tarashima and Noriaki Minakawa : 4'-チオRNAのCRISPR CAS9法への応用, 日本核酸医薬学会第6回年会, Jun. 2021.
49.	Masashi Ohta, Noriko Saito-Tarashima and Noriaki Minakawa : 4'-セレノRNAの性質評価およびsiRNAへの導入, 日本核酸医薬学会第6回年会, Jun. 2021.
50.	Aki Kondoh, KINOSHITA Mao, Noriko Saito-Tarashima and Noriaki Minakawa : STINGアゴニスト作用を有する環状ジヌクレオチドアナログの創製, 創薬懇話会 2021 in 京都, Jun. 2021.
51.	Aki Kondoh, KINOSHITA Mao, Noriko Saito-Tarashima and Noriaki Minakawa : 4-チオフラノースを構成糖にもつ環状ジヌクレオチドアナログの合成と免疫誘導評価, 日本ケミカルバイオロジー学会第15回年会, Jun. 2021.
52.	Masashi Ohta, Noriko Saito-Tarashima, 高橋宏美, 近藤次郎 and Noriaki Minakawa : 4'-セレノRNAの化学合成・性質評価・医薬分子への導入, 第19回次世代を担う有機化学シンポジウム, May 2021.
53.	Noriko Saito-Tarashima and Noriaki Minakawa : セントラルドグマを化学し，新しい創薬モダリティを提案する, 日本薬剤学会第36年会, May 2021.
54.	Noriko Saito-Tarashima, 松尾礼子 and Noriaki Minakawa : 4-チオフラノースを構成糖に持つ人工核酸による遺伝子発現, 日本化学会第101春季年会, Mar. 2021.
55.	Noriko Saito-Tarashima, Yusuke Kumanomidoh and Noriaki Minakawa : イミダゾール型環状ジヌクレオチド誘導体の合成研究, 日本薬学会第140年会, Mar. 2020.
56.	Mao Kinoshita, Noriko Saito-Tarashima and Noriaki Minakawa : c-di-4'-thioAMPの合成と自然免疫誘導能の評価, 日本薬学会第140年会, Mar. 2020.
57.	Mana Ueno, Noriko Saito-Tarashima and Noriaki Minakawa : 4'-チオガイドRNAを利用するゲノム編集の試み, 日本薬学会第140年会, Mar. 2020.
58.	Hiroya Kawano, Noriko Saito-Tarashima and Noriaki Minakawa : 抗デングウイルス活性の増強を目指したイミダゾールヌクレオシド誘導体の合成研究, 日本薬学会第140年会, Mar. 2020.
59.	Tomoya Wada, Mayu Yamada, Noriko Saito-Tarashima and Noriaki Minakawa : siRNA-タンパク質間相互作用解析のための標的捕捉型ケミカルプローブ導入siRNAの創製と性質評価, 日本薬学会第140年会, Mar. 2020.
60.	Noriko Saito-Tarashima : 環状ジヌクレオチド類を基盤とする創薬化学研究, 第3回徳島大学統合的がん創薬研究クラスター合同ミーティング, Dec. 2019.
61.	Noriko Saito-Tarashima : RNA干渉創薬の実現へ向けたケミカルアプローチ, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
62.	Mana Ueno, Noriko Saito-Tarashima and Noriaki Minakawa : ゲノム編集に利用可能な4'-チオガイドRNAの開発, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
63.	Katsuyuki Terauchi, Noriko Saito-Tarashima and Noriaki Minakawa : ホスホロチオエート型c-di-AMPプロドラッグの合成研究, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
64.	Yusuke Kumanomidoh, Noriko Saito-Tarashima and Noriaki Minakawa : イミダゾール型環状ジヌクレオチドc-di-ZMPの合成, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
65.	Mao Kinoshita, Noriko Saito-Tarashima, Yusuke Kumanomidoh and Noriaki Minakawa : 4'-位に硫黄原子を有する環状ジヌクレオチドの合成と自然免疫誘導能の評価, 日本核酸医薬学会第5回年会, Jul. 2019.
66.	Motoki Nakamura, Noriko Saito-Tarashima, Yuki Okano, 黒沢まどか, 岩部愛, 渡辺匡史, 加藤文博, 日紫喜隆行, 藤室雅弘 and Noriaki Minakawa : 抗デングウイルス活性を有するイミダゾールヌクレオシド類の開発研究, 日本核酸医薬学会第5回年会, Jul. 2019.
67.	Mayu Yamada, Tomoya Wada, Noriko Saito-Tarashima and Noriaki Minakawa : ヌクレオシドケミカルプローブ②: 光反応性ケミカルプローブ7dia-deAの改良合成法の開発研究, 日本核酸医薬学会第5回年会, Jul. 2019.
68.	Yusuke Kumanomidoh, Noriko Saito-Tarashima and Noriaki Minakawa : 環状ジヌクレオチドアナログc-di-ZMPの合成, 日本核酸医薬学会第5回年会, Jul. 2019.
69.	Masashi Ohta, Noriko Saito-Tarashima, 高橋宏美, 近藤次郎 and Noriaki Minakawa : 4種のヌクレオチドがセレノ修飾された完全修飾型4'-セレノRNAの合成と性質解析, 日本核酸医薬学会第5回年会, Jul. 2019.
70.	Tomoya Wada, Mayu Yamada, Noriko Saito-Tarashima and Noriaki Minakawa : ヌクレオシドケミカルプローブ①: siRNA-タンパク質間相互作用様式の解明に向けた光反応性ケミカルプローブの開発研究, 日本核酸医薬学会第5回年会, Jul. 2019.
71.	松尾礼子, Noriko Saito-Tarashima and Noriaki Minakawa : 4'-チオ核酸類によって構成されるセントラルドグマの構築, 日本核酸医薬学会第5回年会, Jul. 2019.
72.	Noriko Saito-Tarashima, 松尾礼子 and Noriaki Minakawa : 4'-チオ核酸により構成されるネオセントラルドグマの確立, 日本薬学会第139年会, Mar. 2019.
73.	Mayu Yamada, Tomoya Wada, Noriko Saito-Tarashima and Noriaki Minakawa : RNA結合タンパク質捕捉のためのヌクレオシド型ケミカルプローブの開発研究, 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2018.
74.	Yusuke Kumanomidoh, Noriko Saito-Tarashima, Yohsuke Igata, Naoki Yamaguchi and Noriaki Minakawa : 亜リン酸の段階的活性化に基づく環状ジヌクレオチド類合成法の開発, 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2018.
75.	Motoki Nakamura, 岡野裕貴, 黒沢まどか, Noriko Saito-Tarashima, 日紫喜隆行, 加藤文博, 渡部匡史, 藤室雅弘 and Noriaki Minakawa : イミダゾールヌクレオシドを基盤とする抗デングウイルス剤の創製研究, 第57回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2018.
76.	黒澤まどか, 日紫喜隆之, 加藤文博, Yuki Okano, Noriko Saito-Tarashima, Noriaki Minakawa, 渡部匡史 and 藤室雅弘 : 抗デングウイルス化合物の探索, 第66回日本ウイルス学会学術集会, Oct. 2018.
77.	Noriko Saito-Tarashima, Yohsuke Igata, Kazuto Shiraishi, Kazuhiro Furukawa and Noriaki Minakawa : mRNAの構造変化を誘起するヌクレオチド誘導体の創製 –c-di-4'-thioAMPの合成とリボスイッチに対する結合親和性評価–, 日本核酸医薬学会第4回年会, Jul. 2018.
78.	Noriko Saito-Tarashima, Yohsuke Igata, Kazuto Shiraishi, Kazuhiro Furukawa and Noriaki Minakawa : mRNAの構造変化を誘起する中分子化合物の創製 –c-di-4'-thioAMPの合成とリボスイッチに対する結合親和性評価–, 日本ケミカルバイオロジー学会第13回年会, Jun. 2018.
79.	大島康史, Hasan Mahadi, Noriko Saito-Tarashima, 濱進, Tatsuya Fukuta, Tamotsu Tanaka, Noriaki Minakawa and Kentaro Kogure : 微弱電流処理を利用した機能性核酸の細胞内取り込みの検討, 日本薬学会138年会, Mar. 2018.
80.	Tomoki Takahashi, Seigi Yamamoto, 江村智子, 日高久美, Noriko Saito-Tarashima, 遠藤政幸, 杉山弘 and Noriaki Minakawa : iRedを骨格とした核酸ナノ構造体の開発研究, 日本薬学会第138年会, Mar. 2018.
81.	Naomichi Morita, Noriko Saito-Tarashima and Noriaki Minakawa : 環状ジヌクレオチドミミックの合成と機能評価, 日本薬学会第138年会, Mar. 2018.
82.	黒澤まどか, 日紫喜隆行, 加藤文博, Yuki Okano, Noriko Saito-Tarashima, Noriaki Minakawa, Atsushi Nakayama, Kosuke Namba, 渡部匡史 and 藤室雅弘 : レプリコンアッセイ法を用いた抗デングウイルス化合物の探索, 日本薬学会第138年会, Mar. 2018.
83.	Seigi Yamamoto, Noriko Saito-Tarashima and Noriaki Minakawa : Development of nucleic acid medicine delivery system using photo- responsive nucleic acid nanostructure, 日本化学会第98春季年会, Mar. 2018.
84.	Noriko Saito-Tarashima and Noriaki Minakawa : 核酸‐タンパク質間相互作用解析のためのケミカルアプローチ, 2017年度生命科学系学会合同年次大会, Dec. 2017.
85.	Kentaro Kogure, 大島康史, Tasuku Torao, 三村美夕紀, 藤川昂樹, Hasan Mahadi, 濱進, Tatsuya Fukuta, Noriko Saito-Tarashima, Tamotsu Tanaka and Noriaki Minakawa : 微弱電流処理による高分子医薬の細胞質送達と機能発現, 第39回生体膜と薬物の相互作用シンポジウム, Oct. 2017.
86.	大島康史, 虎尾祐, 三村美夕紀, Hasan Mahadi, Noriko Saito-Tarashima, 濱進, Tatsuya Fukuta, Tamotsu Tanaka, Noriaki Minakawa and Kentaro Kogure : ユニークなエンドサイトーシスを誘起する微弱電流を利用した機能性核酸の細胞質送達, 第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2017.
87.	Kohki Matsumoto, 与那覇乙梨恵, Noriko Saito-Tarashima and Noriaki Minakawa : DDD:AAA型水素結合様式を持つ人工塩基対の合成と性質解析, 第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2017.
88.	Masashi Ohta, Kazuki Ishii, Noriko Saito-Tarashima and Noriaki Minakawa : 4'-セレノRNAの合成並びに性質解析, 第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2017.
89.	黒澤まどか, 渡部匡史, 日紫喜隆行, 加藤文博, Yuki Okano, Noriko Saito-Tarashima, Noriaki Minakawa and 藤室雅弘 : Replicon assay法を用いた抗デングウイルス化合物の探索, 第67回日本薬学会近畿支部総会・大会, Oct. 2017.
90.	岩部愛, 渡部匡史, 日紫喜隆行, 加藤文博, 岡野裕貴, Noriko Saito-Tarashima, Noriaki Minakawa and 藤室雅弘 : 核酸誘導体を活用した抗デングウイルス剤の開発, 第67回日本薬学会近畿支部総会・大会, Oct. 2017.
91.	田中里歩, 渡部匡史, Yuki Okano, Noriko Saito-Tarashima, Noriaki Minakawa and 藤室雅弘 : 核酸誘導体を用いた抗HSV-1化合物の探索, 第67回日本薬学会近畿支部総会・大会, Oct. 2017.
92.	Seigi Yamamoto, Ryohei Nakano, Noriko Saito-Tarashima and Noriaki Minakawa : 核酸医薬分子を組み込んだDNAナノ構造体の構築とその性質, 日本核酸医薬学会第3回年会, Jul. 2017.
93.	Noriaki Minakawa, Noriko Saito-Tarashima, Tomoki Takahashi, Seigi Yamamoto, Nozomi Kinjoh, Hidenori ANDO, Tatsuhiro Ishida and Kentaro Kogure : 化学修飾DNAを利用したRNA創薬, 第33回日本DDS学会学術集会, Jul. 2017.
94.	Tomoya Wada, Noriko Saito-Tarashima and Noriaki Minakawa : ケミカルプローブ導入siRNAを用いたパターン認識受容体との相互作用解析, 日本ケミカルバイオロジー学会第12回年会, Jun. 2017.
95.	Yohsuke Igata, Kazuyuki Sagara, Noriko Saito-Tarashima and Noriaki Minakawa : 核酸分子の簡便精製を可能とする`キャッチ&リリース'タグの開発, 日本ケミカルバイオロジー学会第12回年会, Jun. 2017.
96.	Noriko Saito-Tarashima, Tomoya Wada and Noriaki Minakawa : RNA-タンパク質間相互作用解析のためのケミカルアプローチ, 日本ケミカルバイオロジー学会第12回年会, Jun. 2017.
97.	Kentaro Kogure, 藤川昂樹, Hasan Mahadi, 濱進, Tamotsu Tanaka, Noriko Saito-Tarashima and Noriaki Minakawa : 微弱電流による新規核酸iRedの細胞内送達と遺伝子発現制御, 遺伝子・デリバリー研究会第17回シンポジウム, May 2017.
98.	Masashi Ohta, Noriko Saito-Tarashima, Kazuki Ishii and Noriaki Minakawa : 4'-セレノリボヌクレオシド類の効率的合成とRNAオリゴマー導入の試み, 日本薬学会第137年会, Mar. 2017.
99.	Tomoya Wada, Noriko Saito-Tarashima, 吉良太孝 and Noriaki Minakawa : siRNA-パターン認識受容体の相互作用解析のためのケミカルアプローチ, 日本薬学会第137年会, Mar. 2017.
100.	Yohsuke Igata, Kazuyuki Sagara, Noriko Saito-Tarashima and Noriaki Minakawa : 核酸分子の簡便精製を可能とする`Catch & Release' 法の開発, 日本薬学会第137年会, Mar. 2017.
101.	藤澤絋希, 太田智絵, 中村誠宏, 松田久司, 日紫喜隆行, 加藤文博, Yuki Okano, Noriko Saito-Tarashima, Noriaki Minakawa, 伊藤早織, 渡部匡史 and 藤室雅弘 : ワイン発酵残渣由来化合物と核酸誘導体からの抗デングウイルス化合物の探索, 日本薬学会第137年会, Mar. 2017.
102.	伊藤早織, 藤澤絋希, 渡部匡史, 日紫喜隆行, 加藤文博, Yuki Okano, Noriko Saito-Tarashima, Noriaki Minakawa and 藤室雅弘 : 核酸構造を活用した抗デングウイルス化合物の探索, 日本薬学会第137年会, Mar. 2017.
103.	Noriko Saito-Tarashima, Tomoya Wada, 吉良太孝 and Noriaki Minakawa : RNA-タンパク質間の動的な相互作用解析のためのケミカルアプローチ―真に医薬応用可能な化学修飾siRNAの理論的設計法の確立へ向けて―, 第34回メディシナルケミストリーシンポジウム, Dec. 2016.
104.	Kentaro Kogure, Mahadi Hasan, Noriko Saito-Tarashima, Kohki Fujikawa, 濱進, Tamotsu Tanaka, 樫田啓, 浅沼浩之, Hiroyuki Saito and Noriaki Minakawa : 微弱電流による機能性核酸の効率的な細胞質送達, 日本核酸医薬学会第2回年会(東京), Dec. 2016.
105.	井形陽佑, 相良和幸, Noriko Saito-Tarashima and Noriaki Minakawa : `キャッチ&リリース'法を用いたオリゴヌクレオチドの簡便精製法の開発, 日本核酸医薬学会第2回年会, Nov. 2016.
106.	和田知也, Noriko Saito-Tarashima, 吉良太孝 and Noriaki Minakawa : RNA-タンパク質間相互作用解明のためのケミカルツールの創製, 第55回日本薬学会・日本薬剤師会・日本病院薬剤師会・中国四国支部学術大会, Nov. 2016.
107.	和田知也, Noriko Saito-Tarashima and Noriaki Minakawa : ケミカルプローブを利用したsiRNA-タンパク質間相互作用における分子認識機構の解明, 第21回プロセス化学東四国フォーラムセミナー, Oct. 2016.
108.	藤澤絋希, 伊藤早織, 渡部匡史, 太田智絵, 中村誠宏, 松田久司, 日紫喜隆行, 加藤文博, 岡野裕貴, Noriko Saito-Tarashima, Noriaki Minakawa and 藤室雅弘 : ワイン発酵残渣と核酸誘導体を用いた抗デングウイルス化合物の探索, 第66回日本薬学会近畿支部総会・大会, Oct. 2016.
109.	伊藤早織, 藤澤絋希, 渡部匡史, 日紫喜隆行, 加藤文博, 岡野裕貴, Noriko Saito-Tarashima, Noriaki Minakawa and 藤室雅弘 : 核酸誘導体を骨格とした抗デングウイルス化合物の探索, 第66回日本薬学会近畿支部総会・大会, Oct. 2016.
110.	太田雅士, 石井和貴, Noriko Saito-Tarashima and Noriaki Minakawa : 超原子価ヨウ素を用いた4'-セレノプリンリボヌクレオシドの効率的合成法の開発研究, 第20回プロセス化学東四国フォーラムセミナー, Jun. 2016.
111.	Hasan Mahadi, Noriko Saito-Tarashima, Kohki Fujikawa, Takashi Ohgita, Susumu Hama, Tamotsu Tanaka, Hiroyuki Saito, Noriaki Minakawa and Kentaro Kogure : Intracellular delivery of a novel functional nucleic acid iRed by faint electric treatment for effective regulation of target genes, 第32回DDS学術集会, Jun. 2016.
112.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : 悪性胸膜中皮腫治療における新規shRNA発現化学修飾核酸の有用性の検討, 日本薬剤学会第31年会, May 2016.
113.	Kazuto Shiraishi, Keiji Murakami, Noriko Saito-Tarashima, Kazuhiro Furukawa, Yoichiro Miyake and Noriaki Minakawa : ホスホジエステラーゼ抵抗性を有する4'-チオ化学修飾型環状ジヌクレオチドの合成と評価, 日本薬学会第136年会, Mar. 2016.
114.	谷川真理, Noriko Saito-Tarashima and Noriaki Minakawa : 新規蛍光性ヌクレオシドの合成と性質解析, 日本薬学会第136年会, Mar. 2016.
115.	高橋知樹, Noriko Saito-Tarashima, 御牧夕希子 and Noriaki Minakawa : 新規遺伝子発現抑制デバイスiRedの開発と完全化学合成に向けた検討, 日本薬学会第136年会, Mar. 2016.
116.	岡野裕貴, 伊藤早織, 渡部匡史, Noriko Saito-Tarashima, 日紫喜隆行, 加藤文博, 藤室雅弘 and Noriaki Minakawa : 抗RNAウイルス活性の増強を目指したヌクレオシドリン酸プロドラッグの合成, 日本薬学会第136年会, Mar. 2016.
117.	上田夏瑞, Noriko Saito-Tarashima, 三木和也, 山村桃子, Naoshi Yamazaki and Noriaki Minakawa : iRedを利用した持続的microRNA補充法の開発, 日本薬学会第136年会, Mar. 2016.
118.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Intelligent shRNA expression deviceのin vitro, in vivoにおける有用性評価, 日本薬学会第136年会, Mar. 2016.
119.	Noriko Saito-Tarashima and Noriaki Minakawa : 人工塩基対の酵素認識に基づくダンベル型遺伝子発現デバイスの創製, 日本核酸医薬学会第1回年会, Dec. 2015.
120.	Kazuya Miki, Momoko Yamamura, Noriko Saito-Tarashima, Naoshi Yamazaki, Noriaki Minakawa and Yoshiharu Takiguchi : 新規機能性RNA発現デバイスiRedを用いたmiRNA産生による遺伝子発現抑制効果の検討, BMB2015 第38回日本分子生物学会年会・第88回日本生化学会大会合同大会, Dec. 2015.
121.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Intelligent RNA expression devise(iRed)による標的遺伝子抑制に関する検討, 第37回生体膜と薬物の相互作用シンポジウム, Nov. 2015.
122.	白石和人, Keiji Murakami, Noriko Saito-Tarashima, Kazuhiro Furukawa, Yoichiro Miyake and Noriaki Minakawa : 糖部修飾型環状ジヌクレオチドの合成と評価, 創薬懇話会2015 in 徳島, Jul. 2015.
123.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : 新規RNAi分子発現核酸デバイスのin vitro, in vivo有用性評価, 第31回日本DDS学会学術集会, Jul. 2015.
124.	白石和人, Keiji Murakami, Noriko Saito-Tarashima, Kazuhiro Furukawa, Yoichiro Miyake and Noriaki Minakawa : Cyclic-di-4'-S-adenosine monophosphate (c-di-SAMP)の合成と評価, 第17回プロセス化学東四国フォーラムセミナー, Jun. 2015.
125.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : 新規RNAi分子発現核酸デバイスを用いた標的遺伝子発現抑制効果, 日本膜学会第37年会, May 2015.
126.	Noriko Saito-Tarashima and Noriaki Minakawa : 人工塩基対を利用した第2世代intelligent RNA expression device (iRed) の開発研究, 遺伝子・デリバリー研究会第15回シンポジウム, May 2015.
127.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : 胸腔内がん治療を目指した新規核酸デバイスの有用性評価, 遺伝子・デリバリー研究会第15回シンポジウム, May 2015.
128.	Noriko Saito-Tarashima, 小島孝光, Nozomi Kinjoh, Kazuhiro Furukawa, Hidenori ANDO, Tatsuhiro Ishida and Noriaki Minakawa : New strategy for suppression of gene expresstion using intelligent RNA expressing device (iRed), 日本化学会第95春季年会, Mar. 2015.
129.	谷川真理, Noriko Saito-Tarashima, Kazuhiro Furukawa and Noriaki Minakawa : トリアザペンタレン型蛍光核酸の合成とRNAオリゴマーへの導入, 日本薬学会第135年会, Mar. 2015.
130.	Noriko Saito-Tarashima, 小島孝光, Nozomi Kinjoh, Kazuhiro Furukawa, Hidenori ANDO, Tatsuhiro Ishida and Noriaki Minakawa : Intelligent RNA expressing device (iRed)を利用した核酸創薬の新手法, 第32回メディシナルケミストリーシンポジウム, Nov. 2014.
131.	谷川真理, Noriko Saito-Tarashima, Kazuhiro Furukawa and Noriaki Minakawa : トリアザペンタレン型新規蛍光核酸の合成, 第53回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2014.
132.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Intelligent RNA expressing devise(iRed)の細胞内導入による標的遺伝子抑制, 第53回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2014.
133.	Kazuya Miki, Naoshi Yamazaki, Hirotaka Kira, Noriko Saito-Tarashima, Kazuhiro Furukawa, Noriaki Minakawa and Yoshiharu Takiguchi : ナノ核酸デバイスを用いたsiRNAオフターゲット効果の抑制, 第53回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2014.
134.	Noriko Saito-Tarashima, 林弘也, 寺崎真樹, Kazuhiro Furukawa and Noriaki Minakawa : 4'-セレノRNAの化学合成-鎖切断機構の解明とその効率的合成法の開発―, 第15回プロセス化学東四国フォーラムセミナー, Sep. 2014.
135.	Noriko Saito-Tarashima, 林弘也, Kazuhiro Furukawa and Noriaki Minakawa : 4'-セレノヌクレオシド含有オリゴヌクレオチド合成における鎖切断機構の解明とその解決法, 第44回複素環化学討論会, Sep. 2014.
136.	Noriko Saito-Tarashima, 齋藤陽太, Yosuke Hashimoto, Kazuhiro Furukawa, Tatsuhiro Ishida and Noriaki Minakawa : ハイブリッド型化学修飾核酸2´-O-MOE-4´-thioRNAの合成とアンチmiRNAとしてのin vitro/vivo機能評価, アンチセンス・遺伝子・デリバリーシンポジウム2014, Sep. 2014.
137.	Nozomi Kinjoh, Hidenori ANDO, Noriko Saito-Tarashima, Noriaki Minakawa and Tatsuhiro Ishida : Intelligent RNA expressing devise(iRed)のin vitroにおける標的遺伝子抑制に関する検討, ナノライフサイエンス・オープンセミナー2014, Aug. 2014.
138.	Noriko Saito-Tarashima, 吉良太孝, Naoshi Yamazaki, Kazuhiro Furukawa and Noriaki Minakawa : ナノ核酸デバイスを利用したsiRNA-タンパク質相互作用における分子認識機構の解明, 創薬懇話会2014in岐阜, Jul. 2014.
139.	Noriko Saito-Tarashima, Naoshi Yamazaki, Kazuhiro Furukawa and Noriaki Minakawa : 人工塩基対ImNN :NaO0 のPCR増幅とRNAi創薬への応用, 日本薬学会第134年回, Mar. 2014.
140.	宮澤忠, 梅崎浩平, Noriko Saito-Tarashima, Kazuhiro Furukawa, Takashi Ooi and Noriaki Minakawa : 新規1, 2-ジチアンヌクレオシドの合成と性質, 第52回日本薬学会・薬剤師会・日本病院薬剤師会・中国四国支部学術大会, Oct. 2013.
141.	Noriko Saito-Tarashima and Noriaki Minakawa : 新規Im:Na塩基対のDNAポリメラーゼによる基質認識, 日本薬学会第133年会, Mar. 2013.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Development of a kilo-scale DNA chemical synthesis based on phosphofluoridate exchange reactions. (Project/Area Number: 24K22023 )
Establishment of next-generation drug discovery platform for viral infections (Project/Area Number: 24K02149 )
mRNA医薬開発を加速する人工核酸技術の創出 (Project/Area Number: 22K06527 )
Novel cell system developed by chemistry (Project/Area Number: 21K19052 )
Treatment and prevention of RNA virus infections based on 4'-thionucleic acid technology (Project/Area Number: 21H02606 )
Development of microRNA to eat: Nucleic acid as a supplement food (Project/Area Number: 19K22287 )
Medicinal chemistry targeting STING for cancer immunotherapy (Project/Area Number: 19K16316 )
Development of photoresponsive DNA nanostructure to accerelate iRed based nucleic acid medicine (Project/Area Number: 18H02108 )
Medicinal chemistry on cyclic dinucleotides as immunotherapeutic agents. (Project/Area Number: 17K15481 )
Elucidation of interaction between siRNA and pattern recognition receptors toward systematic siRNA drug design (Project/Area Number: 15H06446 )
Search by Researcher Number (90755183)

Associate Professor : Saito-Tarashima, Noriko

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)